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ABSTRACT
The cardiac sarco/endoplasmic reticulum calcium ATPase (SERCA) establishes the
intracellular calcium gradient across the sarcoplasmic reticulum membrane. It has been
proposed that SERCA forms homo-oligomers that increase the catalytic rate of calcium
transport. We investigated SERCA oligomerization in rabbit left ventricular myocytes
using a photoactivatable cross-linker. Western blotting of cross-linked SERCA revealed
higher molecular weight species consistent with SERCA oligomerization. Fluorescence
resonance energy transfer (FRET) measurements in cells transiently transfected with
fluorescently-labeled SERCA2a revealed that SERCA readily forms homo-dimers. These
dimers formed in the absence or presence of the SERCA regulatory partner,
phospholamban (PLB) and were unaltered by PLB phosphorylation or changes in calcium
or ATP. Fluorescence lifetime data are compatible with a model in which PLB interacts
with a SERCA homo-dimer in a stoichiometry of 1:2. Functional data show that homodimerization of SERCA is an important component of SERCA regulation. Together, these
results suggest that SERCA forms constitutive homo-dimers in live cells that and dimer
formation is not modulated by SERCA conformational poise, PLB binding, or PLB
phosphorylation.
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CHAPTER ONE
CARDIAC CALCIUM ATPASE AND THE HEART
The heart is essential for providing adequate blood flow to meet the demands of
the body; blood carries oxygen and nutrients to cells and removes carbon dioxide and
metabolites. Heart failure (HF) arises when the heart is unable to meet the demand for
oxygen, and is one of the leading causes of morbidity and mortality worldwide
(Mozaffarian, Benjamin et al. 2016). Clinical treatment of cardiovascular diseases, such
as HF, continues to be a leading health care cost and places a substantial financial
burden on healthcare (Mozaffarian, Benjamin et al. 2016). Advances in HF treatment
from the period 1950-1969 to 1990-1999 reduced one-year mortality rates in men from
30% to 28% and in women from 28% to 24% (Levy, Kenchaiah et al. 2002). Despite these
incremental advances, the mortality rates remain unacceptably high with five-year
mortality greater than 50% (Roger, Weston et al. 2004). There is currently no cure for
HF.
Sarco/endoplasmic reticulum calcium ATPase (SERCA) is responsible for
transporting calcium from the cytoplasm/sarcoplasm to the luminal side of the
endoplasmic/sarcoplasmic reticulum (ER/SR). It is also the primary means by which
calcium is removed from the sarcoplasm. This process sequesters calcium in the SR
lumen. In the heart this process is essential for relaxation of the myocardium, as calcium
is a necessary signaling molecule that enables actin and myosin interactions to drive
1
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muscle contraction (Bers 2002). In addition to altering relaxation of the heart, SERCA
also affects contraction as the sequestered SR calcium load influences the strength of
subsequent contractions.
Figure 1 shows the general process of calcium handling for cardiac myocyte
contraction and relaxation. Depolarization across the sarcolemma membrane opens Ltype calcium channels (LTCC), causing an influx of calcium into the sarcoplasm. This
induces calcium release from the SR lumen through the ryanodine receptor (RyR) in a
process termed calcium-induced calcium release (CICR). Sarcoplasmic calcium binds to
troponin C on the myofilaments and a series of coordinated events exposes binding sites
on actin, allowing myosin and actin to contract. Relaxation is produced by removal of
calcium from the sarcoplasm though SERCA, plasma membrane calcium ATPase (PMCA),
or the sodium/calcium exchanger (NCX). SERCA accounts for approximately 70% of
calcium removal and readies the myocyte for subsequent contractions.
Previous studies have demonstrated that calcium handling is altered in HF
(Gwathmey, Copelas et al. 1987). End-diastolic cytosolic calcium levels are found to be
elevated in human failing myocardium (Gwathmey, Warren et al. 1991, Beuckelmann,
Nabauer et al. 1992). Multiple studies showed that SR calcium stores are decreased in
human failing myocardium (Lindner, Erdmann et al. 1998, Piacentino, Weber et al. 2003)
alongside a reduction in calcium uptake into the SR (Pieske, Maier et al. 1999). These
changes are characterized by a blunted calcium transient with elevated sarcoplasmic
baseline calcium, slower calcium release from the SR stores, reduced peak amplitude of
release, and slower calcium reuptake rates
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Figure 1. Schematic representation of calcium handling in the cardiac myocyte.
Depolarization of the sarcolemmal membrane opens L-type calcium channels (LTCC),
allowing calcium into the cell. The increase in intracellular calcium opens ryanodine
receptors (RyR), releasing calcium from the SR stores and increasing the sarcoplasmic
calcium concentrations further. The elevated intracellular calcium binds to
myofilaments and activates contraction through the action of myosin. Relaxation is
produced by removal of calcium through the plasma membrane calcium ATPase
(PMCA), the sodium calcium exchanger (NCX), or sarco/endoplasmic calcium ATPase
(SERCA). SERCA is inhibited by phospholamban (PLB), but this inhibition can be
alleviated by phosphorylation of PLB through protein kinase A (PKA) or
calcium/calmodulin-dependent protein kinase II (CaMKII).
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(Beuckelmann and Erdmann 1992, Piacentino, Weber et al. 2003). This results in
weaker muscle contractions, longer time to relax, and reduced cardiac output. As the
chief constituent of calcium handling, SERCA presents an attractive target for correcting
disordered calcium handling as a possible treatment for HF.
In the heart, SERCA is predominantly regulated through a 52 amino acid
inhibitory peptide called phospholamban (PLB, Figure 1). PLB inhibits SERCA by reducing
the apparent affinity for calcium, thus decreasing the SERCA calcium transport rate over
the physiological range of calcium concentrations. Relief of inhibition by PLB can be
overcome by phosphorylation of PLB at serine 16 by protein kinase A (PKA) or by
calcium calmodulin protein kinase II (CaMKII) at threonine 17 (Tada, Kirchberger et al.
1975, Plank, Pifl et al. 1983, Simmerman, Collins et al. 1986). SERCA is a primary target
of beta-adrenergic signaling through PLB phosphorylation by PKA, and an important
component for increasing both inotropy and lusitropy in response to demand for higher
cardiac output. In addition to altering calcium sensitivity of the SERCA pump, some
evidence suggests that PLB also increases the maximal rate of transport (V max). Studies
show that when phosphorylated PLB is present Vmax is increased beyond what can be
achieved in the absence of PLB (Antipenko, Spielman et al. 1997, Reddy, Cornea et al.
2003). This may be an additional regulatory mechanism for enhanced calcium transport
that uniquely relies on the presence of phosphorylated PLB.
Evidence suggests that, in addition to regulation by PLB, SERCA activity may also
be regulated by assembly into homo-oligomers. Data show that this could be an
inhibitory mechanism where SERCA protomers form aggregates in the membrane that
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have reduced ATPase activity (Voss, Jones et al. 1994, Mersol, Kutchai et al. 1995). Other
experiments show that SERCA protomers form specific oligomers that may enhance
calcium transport through cooperative mechanisms. It has also been suggested that
phosphorylated PLB may be a requirement for this cooperative action (Negash, Chen et
al. 1996). However, these models have not been widely adopted, in part because
detergent-solubilized SERCA has been shown to couple hydrolysis of ATP with calcium
transport (Dean and Tanford 1978, Vilsen and Andersen 1987). Whether these
solubilization conditions produce only monomeric SERCA and whether homooligomerization is a necessary component of activity is still not clear. This necessitates a
greater understanding of calcium transport across the SR membrane.
The SERCA/PLB regulatory complex may include additional partners that regulate
SERCA function. Previous studies have shown that a mitochondrial anti-apoptotic
protein HS-1 associated protein X-1 (HAX-1) interacts with PLB (Vafiadaki, Sanoudou et
al. 2007). Data suggest that HAX-1 regulates cardiac performance by promoting
formation of PLB monomers which readily inhibit SERCA. Further evidence supports cellsurvival mediated by the interaction between PLB and HAX-1. The exact role of this
protein in the regulatory complex has not been fully fleshed out.
An area of study that remains unresolved is how phosphorylation of the cytosolic
domain of PLB causes relief of SERCA inhibition. Our previous work has examined two
models that explain how PLB inhibition is relieved. The first model proposes that
phosphorylation of PLB causes unbinding from SERCA; this frees up SERCA to actively
pump calcium (James, Inui et al. 1989, Kimura, Kurzydlowski et al. 1997, Chen, Akin et al.
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2006). Our own studies and studies by other groups have supported a second model
where phosphorylated PLB remains bound to SERCA (Negash, Yao et al. 2000, Bidwell,
Blackwell et al. 2011). Regardless of the mechanism for relief of inhibition, neither
model provides a complete understanding for the role of PLB phosphorylation on
altered SERCA calcium sensitivity. Previous studies by our group have shown that there
is a small structural change upon phosphorylation (Hou, Kelly et al. 2008).
We set out to examine the regulatory complex in more detail and investigate the
role of homo-oligomerization on SERCA function.

CHAPTER TWO
REVIEW OF RELATED LITERATURE
SERCA is a member of the ion-motive P-type ATPase family, which includes
transporters such as the Na+/K+-ATPase and the H+/K+-ATPase, and H+-ATPase (Apell
2004). P-type ATPases establish and maintain important electrochemical gradients that
drive many essential cellular processes. ATPases pump ions across membranes, usually
against their concentration gradients, by utilizing energy from ATP. The P-type ATPase
family is highly homologous and characterized by four important domains: the
nucleotide binding domain (N), the actuator domain (A), the phosphorylation domain
(P), and the transmembrane domain (TM). The soluble A-, N-, and P-domains sit within
the cytosolic lumen, while the TM-domain anchors the ATPase in the appropriate
membrane. Most members of the P-type ATPase family contain 10 transmembrane
helices, which dictate ion specificity (Clarke, Loo et al. 1989, Toyoshima, Nakasako et al.
2000, Bublitz, Poulsen et al. 2010).
Discovery and characterization of SERCA
Identification of an SR membrane calcium pump first came from ATP-dependent
calcium uptake experiments in crude SR muscle preparations (Hasselbach and Makinose
1961, Ebashi and Ebashi 1962). These preparations sequestered calcium in SR fractions
and produced relaxation similar to that of application of a calcium chelator. Spinlabeling of SR vesicles showed that SR membrane protein underwent conformational
7
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changes in response to ATP (Landgraf and Inesi 1969, Coan and Inesi 1976). A defining
feature of SERCA calcium transport was first described Inesi, that of calcium
dependence on ATPase activity. At low calcium concentrations there is little ATPase
activity. As calcium concentrations increase, the activity of SERCA increases until it
reaches a maximal rate of transport at saturating calcium. An example of this is shown
in figure 2 (black). Refinement of ATPase measurements later demonstrated
cooperativity of the calcium binding process; the first calcium binds with low affinity and
the second with high affinity (Inesi, Kurzmack et al. 1980). The range of calcium over
which ATPase activity is sensitive occurs from about 30 nM to 2 μM, the approximate
physiological range of calcium in muscle tissue between relaxation (low calcium) and
contraction (high calcium). The calcium threshold for activation of SERCA essentially sets
the resting sarcoplasmic calcium concentration.
In 1970 David MacLennan isolated and purified SERCA from rabbit skeletal
muscle. The purified protein possessed all the hallmarks of what was then known about
SERCA: the requirement for Mg2+ and Ca2+, inhibition by the addition of EGTA, and
inhibition by mersalyl. Additionally, ATPase activity was found to be dependent on an
intact phospholipid membrane, indicating that this protein is a membrane protein
(MacLennan 1970). The molecular weight of purified SERCA was determined to be 102
kDa and partial trypsin digestions helped identify the site of ATP binding and other
features of SERCA structure (Stewart and MacLennan 1976, Reithmeier and MacLennan
1981). In 1985 the cDNA sequence was determined for rabbit skeletal muscle
(MacLennan, Brandl et al. 1985). Later work identified a total of 11 different isoforms:
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Figure 2. A representative ATPase activity curve for SERCA in the absence (black) or
presence of PLB (red). As calcium concentrations increase, the ATPase activity increases
up to a maximal level. PLB produces a characteristic rightward shift in this relationship.
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SERCA1a/b, SERCA2a/b/c, and SERCA3a-f (Brandl, Green et al. 1986, Burk, Lytton et al.
1989, Lytton, Zarain-Herzberg et al. 1989, Gelebart, Martin et al. 2003, Bobe, Bredoux et
al. 2004). SERCA1a is the predominant fast skeletal isoform and is the most studied
isoform due to its abundance in skeletal muscle and ease of purification. SERCA2b is
ubiquitously expressed in all cell types. SERCA2a is the cardiac isoform; however, it is
also expressed in slow skeletal muscle.
SERCA transport mechanism
SERCA ion transport is broadly characterized by transitions between the calciumbound E1 state and the calcium-free E2 state. However, there exist many catalytic
transitions between these two simplified steps. The mechanism of P-type ATPase ion
translocation, termed Post-Albers cycle, was first described in the Na+/K+-ATPase
(Albers 1967, Post, Hegyvary et al. 1972). Briefly, ions bind to the TM-domain followed
by binding of ATP in the N-domain. This is followed by phosphoryl transfer from ATP
that forms a phosphoanhydride intermediate with the P-type ATPase at a highly
conserved aspartic acid residue located in the P-domain. Ion translocation is achieved
through a series of concerted motions that come from the hydrolysis of ATP. These
motions drive the ions through the TM-domain to the opposite side of the membrane
where they are released. SERCA transports two calcium ions from the cytosol to the
ER/SR lumen for every ATP hydrolyzed (Inesi, Kurzmack et al. 1978). In addition, SERCA
countertransports 2 or 3 H+ ions (Yu, Carroll et al. 1993, Stokes and Green 2003). Figure
3 illustrates a simplified Post-Albers scheme for SERCA. Many of these transitions have

11

Figure 3. A Post-Albers schematic representation of SERCA calcium cycling. SERCA in the
E1 state (high calcium affinity) binds ATP and calcium on the cytosolic side. Hydrolysis of
ATP produces a phosphoenzyme intermediate followed by transition to the low calcium
affinity E2 state. Calcium is released into the SR lumen followed by loss of the phosphate
group and a structural transition back to the E1 state.
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been characterized, yielding different rate constants for each step. Importantly, some
of these transitions are faster than others, indicating a rate-limiting step.
SERCA in disease
Only two diseases have been identified specifically originating from mutations to
SERCA. A number of mutations in skeletal SERCA1 isoform have been shown to cause
Brody disease (Karpati, Charuk et al. 1986, Odermatt, Taschner et al. 1996). Brody
disease is characterized by impaired muscle relaxation, cramping, and stiffness.
Mutations in the SERCA2 gene have been linked to Darier’s disease, an autosomal
dominant skin disorder (Dhitavat, Macfarlane et al. 2003). Despite mutations in the
SERCA2 gene, these individuals do not display increased rates of cardiovascular disease
or HF. It is important to note that knockout of cardiac SERCA is embryonic lethal,
indicating that mutations that significantly alter SERCA function would not be tolerated
(Periasamy, Reed et al. 1999).
Alterations to cardiac SERCA expression and regulation during HF have been
observed across a wide range of studies, underscoring the importance of this protein.
SERCA protein and RNA expression have been observed to decrease in HF in guinea pigs
(Kiss, Ball et al. 1995), rats (Komuro, Kurabayashi et al. 1989, de la Bastie, Levitsky et al.
1990), rabbits (Nagai, Zarain-Herzberg et al. 1989), and even dogs (O'Rourke, Kass et al.
1999). Whether changes in SERCA activity and expression are a cause of progression to
HF or whether these changes are simply correlated with HF is a matter of some debate.
However, when SERCA was overexpressed in various animal models of HF, cardiac
function was improved, demonstrating the importance of this protein in cardiac
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pathogenesis (Baker, Hashimoto et al. 1998, Miyamoto, del Monte et al. 2000, Davia,
Bernobich et al. 2001).
Evidence suggests that the alterations in SERCA expression seen in various
animal models might not be present in human cardiomyopathies. Some studies of
human myocardium have shown similar reductions in both SERCA mRNA levels
(Mercadier, Lompre et al. 1990, Arai, Alpert et al. 1993) and protein expression
(Hasenfuss, Reinecke et al. 1994). However, other studies have shown that, while mRNA
levels are decreased, protein levels remain the same (Schmidt, Hajjar et al. 1999,
Munch, Bolck et al. 2002). Patients with HF had similar levels of SERCA protein
compared to those without HF; however SERCA activity was significantly decreased
(Schwinger, Bohm et al. 1995). Additional animal studies corroborate this observation;
Zarain-Herzberg et al. found that SERCA activity was reduced more than expected for
the level of decrease in protein expression (Zarain-Herzberg, Afzal et al. 1996),
suggesting that reduced SERCA function is not entirely due to decreased expression. A
recent clinical trial utilized overexpression of SERCA to treat patients with HF but did not
improve clinical outcomes, indicating that our understanding of SERCA function is
incomplete. Development of such future therapies will require a better understanding
of function and regulation to address the role of depressed SERCA activity in disease.
Discovery and characterization of phospholamban
Evidence for cyclic AMP-dependent kinase targeting the SR membrane was first
described in the early 1970’s by multiple groups (Wollenberger 1972, Wray, Gray et al.
1973, La Raia and Morkin 1974). A potential modulator of SERCA activity was discovered
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when Arnold Katz’s group showed that cardiac SR preparations had increased rates of
calcium uptake following phosphorylation by cyclic AMP-dependent protein kinase
(Kirchberger, Tada et al. 1972). They later identified this phosphorylation as targeting a
22 kDa SR membrane protein (Tada, Kirchberger et al. 1975). Arnold Katz’s wife
suggested naming this protein phospholamban after the greek “phospho” (phosphate)
and “lambano” (to receive) (Katz 1998). Later experiments utilized boiling and detergent
to show that the phospholamban monomer is approximately 5-6 kDa (Will, Levchenko
et al. 1978, Bidlack and Shamoo 1980). The original identification of the 22 kDa species
was more accurately determined to be a stable homo-pentamer with a molecular
weight of 25-30 kDa (Fujii, Kadoma et al. 1986, Wegener, Simmerman et al. 1986). PLB
has also been observed as dimers, trimers, and tetramers on gels, however the
monomer and pentamer are the predominant forms (Thomas, Reddy et al. 1998). It is
thought that the pentamer is an inactive reserve pool of PLB, although some studies
have suggested that the pentamer may form an ion pore or functional channel (Kovacs,
Nelson et al. 1988, Oxenoid and Chou 2005). Förster transfer recovery experiments have
shown that the pentamer is a highly stable complex that exists in dynamic equilibrium
with the monomeric form of PLB, which binds to and inhibits SERCA (Kimura, Asahi et al.
1998, Robia, Campbell et al. 2007).
PLB is composed of an amino-terminal cytosolic alpha helix connected with a
hinge region to a single-pass carboxy-terminal transmembrane alpha helix (Simmerman,
Collins et al. 1986, Simmerman, Lovelace et al. 1989). Crystal structures show that the
transmembrane region of PLB binds to a groove in SERCA formed by the M2, M4, M6,
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and M9 helices of the TM-domain of SERCA (Akin, Hurley et al. 2013). This groove was
also observed to be the site of binding by a PLB homologue, sarcolipin, in skeletal
isoform SERCA1a (Toyoshima, Iwasawa et al. 2013, Winther, Bublitz et al. 2013). The
cytosolic domain of PLB has not been resolved in crystal structures. NMR experiments
have shown that this region possibly exists in equilibrium between different structural
substates (Verardi, Shi et al. 2011).
Stoichiometry of the SERCA/PLB regulatory complex
Extensive cross-linking studies and X-ray crystallography have shown that a
single PLB interacts with SERCA (James, Inui et al. 1989, Akin, Hurley et al. 2013,
Toyoshima, Iwasawa et al. 2013, Winther, Bublitz et al. 2013). However, some evidence
suggests that more than one PLB may interact with SERCA. Two-dimensional cocrystallization of SERCA and PLB showed that the PLB pentamer can interact with SERCA
(Stokes, Pomfret et al. 2006). Further studies showed that mutations promoting
pentamer formation retained inhibitory function, indicating that this might be the active
inhibitory state (Glaves, Trieber et al. 2011). Published co-crystallization studies also
suggested a PLB:SERCA stoichiometry of 1:2 (Young, Jones et al. 2001). Coimmunoprecipitation studies demonstrated that both PLB and SLN can simultaneously
bind SERCA, possibly generating a superinhibitory complex (Asahi, Kurzydlowski et al.
2002, Asahi, Sugita et al. 2003). These studies suggest a secondary binding site and a
possible PLB:SERCA stoichiometry of 2:1. However, most studies support a model of a
single PLB bound to SERCA in a 1:1 stoichiometry (Mueller, Karim et al. 2004). Mutations
that enhance the monomeric form of PLB show an improved ability to inhibit SERCA,
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suggesting that an oligomeric form of PLB is not required for inhibition (Kimura,
Kurzydlowski et al. 1997). Previous measurements of fluorescently-labeled PLB and
SERCA support the model of a single PLB in the regulatory complex (Robia, Campbell et
al. 2007). Many of the studies examining the stoichiometry of the complex have
employed unnatural experimental conditions, thus it may be beneficial to examine this
stoichiometry in a native environment.
Inhibition of SERCA by PLB
PLB inhibits SERCA through physical interaction with SERCA. Inhibition of SERCA
is relieved by PKA phosphorylation of PLB at serine 16 or CaMKII phosphorylation at
threonine 17 (Le Peuch, Haiech et al. 1979, Simmerman, Collins et al. 1986). It is not
clear whether this mechanism works by physical dissociation of PLB from SERCA (Chen,
Akin et al. 2006, Akin, Chen et al. 2010) or whether the two proteins remain bound
during phosphorylation of PLB (Li, Bigelow et al. 2004, Mueller, Karim et al. 2004,
Bidwell, Blackwell et al. 2011). Previous work has shown that stimulation of the betaadrenergic cascade produces a robust phosphorylation of PLB at serine 16 (Tada,
Kirchberger et al. 1975) that increases SERCA activity (Kranias, Garvey et al. 1985).
Phosphorylation makes SERCA a predominant target of beta-adrenergic signaling in the
heart and comprises an important response to demand for increased contractility.
SERCA inhibition can also be relieved by phosphorylation of PLB at threonine 17,
although this probably does not occur independently of PKA serine 16 phosphorylation
in the heart (Plank, Pifl et al. 1983, Lindemann and Watanabe 1985, Simmerman, Collins
et al. 1986, Mundina-Weilenmann, Vittone et al. 1996). Dephosphorylation of both sites
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has been shown to be due to protein phosphatase-1 activity (Kranias and Di Salvo 1986,
Steenaart, Ganim et al. 1992).
As previously shown in figure 2, SERCA activity increases in response to
increasing calcium concentration. PLB inhibits SERCA by decreasing the calcium
sensitivity, resulting in a rightward shift in this relationship (red trace). In fact, the first
experiment on calcium uptake in the cardiac SR took advantage of “half-maximal”
calcium, thus being poised to observe the greatest possible difference between
unphosphorylated and phosphorylated PLB (Kirchberger, Tada et al. 1972). As seen in
figure 2, at calcium concentrations below the maximum ATPase rate, SERCA activity is
reduced when PLB is present. Phosphorylation of PLB will reverse this effect such that
the calcium sensitivity is shifted back to the left.
The maximal calcium ATPase activity may also be altered by PLB. Studies have
identified distinct roles for serine 16 and threonine 17 in regulating SERCA (Mattiazzi,
Hove-Madsen et al. 1994). Maximal calcium uptake rate (Vmax) increased in the presence
of CaMKII phosphorylation (Mattiazzi, Hove-Madsen et al. 1994, Mundina-Weilenmann,
Vittone et al. 1996). One of these studies suggested that Vmax changes were specific to
CaMKII, while PKA phosphorylation only altered calcium sensitivity and not Vmax
(Mattiazzi, Hove-Madsen et al. 1994). Other groups have observed Vmax increases in
systems phosphorylated by PKA. Antipenko et al. reported a 33 – 44% increase in Vmax
upon stimulation with PKA in purified SR (Antipenko, Spielman et al. 1997). This was also
observed by Reddy et al. in a reconstituted system and by Lu et al. in cardiac SR with
nonionic detergent (Lu and Kirchberger 1994, Reddy, Cornea et al. 2003). Trieber et al.
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provided evidence that interaction of PLB with SERCA enhances Vmax even in the
absence of phosphorylation and Vmax was not further altered by phosphorylation
(Trieber, Douglas et al. 2005). ATPase measurements in the presence of synthetic
peptides provided a potential mechanism of SERCA inhibition by PLB. Expression of the
cytosolic region of PLB (amino acids 1 – 31) only decreased the Vmax of SERCA while
expression of the transmembrane region of PLB (amino acids 28 – 47) only decreased
the calcium affinity, differentiating the role of these domains in calcium transport
regulation (Sasaki, Inui et al. 1992). Tryptic digestion of the cytosolic domain of PLB
enhanced Vmax, corroborating the functional role of the cytosolic domain in calcium
transport (Lu, Xu et al. 1993). A variety of experiments have indicated a possible
functional effect of PLB by alteration of Vmax although the exact mechanism by which
PLB would alter Vmax has not been established.
Careful examination of the maximum rate of calcium transport has shown
evidence for increases in Vmax with PLB. This may serve as an additional mechanism for
increased calcium transport in the presence of phosphorylated PLB. However, not all
groups have observed changes in Vmax despite attempts to examine this effect. Morris et
al. did not detect a change in Vmax following phosphorylation with PKA or with
incubation of two antibodies that mimic the effects of PLB (Morris, Cheng et al. 1991).
These results were corroborated in SR preparations from human myocardium, again
showing the failure of an anti-PLB antibody to alter Vmax (Movsesian, Colyer et al. 1990,
Movsesian 1992). Earlier work from Reddy et al. found that PLB had no effect on Vmax in
skeletal SR preparations co-expressed with recombinant PLB. They observed that
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expression of the recombinant cytosolic domain of PLB (residues 1 – 31) had no
apparent effect even at molar ratios as high as 300:1 (Reddy, Jones et al. 1995). Other
studies also reported similar failure of PKA- or CaMKII-mediated phosphorylation to
increase Vmax (Odermatt, Kurzydlowski et al. 1996, Schwinger, Munch et al. 1999). The
inconsistent results obtained from measurements of ATPase activity remains an
unresolved problem in the field and necessitates further examination of this effect.
Phospholamban in disease
A few mutations to PLB have been observed to cause cardiovascular disease. A
mutation of arginine 9 to cysteine results in dilated cardiomyopathy and early death
(Schmitt, Kamisago et al. 2003). Our group has previously characterized this mutant as
being particularly susceptible to oxidative stress, decreasing regulation of SERCA (Abrol,
de Tombe et al. 2015). Another mutation, L39stop, leads to heart failure (Haghighi,
Kolokathis et al. 2003). Previous work has shown that this results in mislocalization of
PLB to the sarcoplasm, reducing physical interaction with SERCA (Abrol, Smolin et al.
2014). Deletion of arginine 14 was found in a family with hereditary HF (Haghighi,
Kolokathis et al. 2006). More recently mutation of arginine 25 to cysteine was shown in
a familial pedigree with dilated cardiomyopathy (Liu, Morales et al. 2015). These
mutations to PLB underscore the importance of proper SERCA regulation and highlight
the role of SERCA in cardiac pathogenesis.
Evidence suggests that PLB protein expression does not change during the
progression to HF (Munch, Bolck et al. 1998, Huang, Wang et al. 1999). However, studies
suggest that phosphorylation of PLB is decreased in HF (Huang, Wang et al. 1999,
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Schwinger, Munch et al. 1999). Measurements of protein expression in rats with
congestive HF found that SERCA:PLB and pentamer:monomer ratios were preserved
while phosphorylation of PLB at serine 16, but not threonine 17, was decreased (Sande,
Sjaastad et al. 2002). These results also showed no change in SERCA expression.
The decrease in PLB phosphorylation alone could explain the reduced SERCA
activity observed in HF, however, multiple studies show a decreased responsiveness to
stimulation by either PKA or CaMKII in failing myocardium. Schmidt et al. observed a
decreased activation of SERCA in response to either PKA or CaMKII, suggesting that
phosphorylation alone could not account for the decreased activity (Schmidt, Hajjar et
al. 1999). Schwinger et al. found that PKA phosphorylation of failing human myocardium
corrected the differences in calcium sensitivity, but a significant decrease in Vmax
persisted (Schwinger, Munch et al. 1999). Blockade of phosphatase activity with okadaic
acid reversed the loss of PLB phosphorylation but did not fully restore calcium transient
amplitudes and rates of relaxation (Huang, Wang et al. 1999). The results seen in these
studies show that the reduced PLB phosphorylation seen in HF does not fully explain the
decrease in SERCA activity, suggesting that an additional mechanism may be involved.
SERCA homo-oligomerization
Multiple studies have provided evidence for the assembly of SERCA into homooligomers. Early work on the skeletal SERCA isoform suggested that SERCA naturally
forms oligomers in muscle tissue preparations. Electron microscopy of reconstituted
purified SERCA in vesicles showed formation of tetramers (Vanderkooi, Ierokomas et al.
1977). In 1984, Yamamoto et al. found that gel filtration of skeletal muscle SR
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preparations produced two distinct fractions containing SERCA, the first at a molecular
weight of approximately 150 kDa and the second at a molecular weight of
approximately 360 kDa, suggesting formation of SERCA homo-dimers (Yamamoto,
Yantorno et al. 1984). Careful analysis of the kinetic properties of calcium transport
provided additional evidence for homo-dimerization (Mahaney, Albers et al. 2005, Chen,
Yao et al. 2009). However, other kinetic studies detailing phosphoenzyme formation and
decay support a model for SERCA homo-trimerization (Mahaney, Thomas et al. 2008).
Higher order oligomerization has also been seen in time-resolved optical anisotropy
measurements revealing the formation of SERCA aggregates in the presence of
thapsigargin or melittin (Voss, Birmachu et al. 1991, Mersol, Kutchai et al. 1995).
Many of the studies investigating oligomerization of SERCA have suggested that
this may be an important regulator of SERCA function. Some studies have correlated
oligomerization/aggregation with decreased SERCA catalytic activity. This observed
inhibition by self-association could be relieved by phosphorylation, which is proposed to
disrupt SERCA self association through charge reversal in the cytosolic region of PLB
(Voss, Jones et al. 1994, Thomas, Reddy et al. 1998). Inhibitory molecules such as
thapsigargin or melittin produced irreversible self association of SERCA (Voss, Birmachu
et al. 1991, Mersol, Kutchai et al. 1995). However, other data suggest that SERCA
oligomerization may be a mechanism for increased transport activity after relief of
inhibition by adrenergic stimulation. In particular, saturation transfer electron
paramagnetic resonance experiments indicated that phosphorylation of PLB reduced
the rotational mobility of SERCA2a consistent with SERCA homo-oligomerization
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(Negash, Chen et al. 1996). This interpretation is also supported by kinetic
measurements of calcium transport that indicated SERCA2a dimerizes in the presence of
phosphorylated PLB (Mahaney, Albers et al. 2005). Earlier work also demonstrated that
SERCA-SERCA interactions altered responsiveness to ATP (Moller, Lind et al. 1980) or
magnesium (Yamamoto, Yantorno et al. 1984, Vilsen and Andersen 1987).
Significantly, the kinetic data suggested conformational coupling of SERCA
protomers into a single functional unit to increase the rate of calcium transport. In this
model energetically unfavorable structural transitions of one SERCA protomer are
assisted by coupling them to energetically favorable conformational changes of another
protomer. Examination of different kinetic transitions of calcium transport revealed that
some steps were enhanced beyond the rate constants of a single protomer (Mahaney,
Albers et al. 2005). By reducing the barrier of the slow step the overall rate of calcium
transport is increased. Radiation inactivation of SERCA showed a reduction in SERCA
activity that was greater than the inactivated fraction of SERCA, suggesting that the
activity of SERCA is greater than the sum of its parts (Chamberlain, Berenski et al. 1983).
An analogous experiment was performed by Chen et al., showing the ATPase activity
was reduced more than would be expected from the molar ratio of WT to inactive
SERCA (Chen, Yao et al. 2009). This process of conformational coupling enables SERCA to
overcome catalytically unfavorable steps by coupling multiple SERCA protomers in a
cooperative manner. These data may provide insight into the discrepancy between
unchanged SERCA expression and depressed function. SERCA homo-oligomerization
may be a key regulatory component of SERCA activity in addition to regulation by PLB.
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Further precedence for SERCA homo-oligomerization comes from studies of
other P-type ATPases. Early cross-linking of the Na+/K+-ATPase with copper and ophenanthroline yielded a tetramer. Interesting, only half of the ATPases were
phosphorylated, suggesting that protomers may act cooperatively through alternating
steps of the catalytic cycle (Askari and Huang 1980). Later work by Kunihiro Mimura et
al. identified tetramer, dimer, and monomer fractions of this enzyme. The tetramer had
half the ATPase activity of the monomer or dimer, suggesting a possible regulatory
mechanism for self-association (Mimura, Tahara et al. 2008). Irradiation experiments of
the gastric H+/K+-ATPase showed that dimerization was necessary for enzyme activity
(Morii, Hayata et al. 1996). Despite the evidence for P-type ATPase oligomerization,
these models have not been widely adopted as the monomeric forms are shown to
possess ATP-dependent ion transport (Goormaghtigh, Chadwick et al. 1986, Andersen
1989).
Interaction of Hax-1 with the SERCA/PLB regulatory complex
HAX-1 was originally identified in a yeast two-hybrid screen as a binding partner
of HS1, a regulator of cell proliferation and death in lymphoid cells (Suzuki, Demoliere et
al. 1997). Immunohistochemistry showed strong mitochondrial localization with some
HAX-1 present in the ER membrane and nuclear envelope. Recent work has provided
evidence for association of HAX-1 with the cytosolic domain of PLB (Vafiadaki, Sanoudou
et al. 2007). Interestingly, western blotting of mouse ventricular myocytes from HAX-1
overexpressing mice showed reduced SERCA protein levels (Vafiadaki, Arvanitis et al.
2009). These studies found higher levels of HAX-1 when PLB was present in the heart
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than when it was absent in a knockout mouse model. In addition, SERCA activity was
more inhibited than the wild type mice, suggesting a regulatory mechanism for HAX-1
that went beyond altering protein expression. In fact, phosphorylation of PLB abrogated
interaction with HAX-1 as determined from co-immunoprecipitation experiments. Of
note, HAX-1 was shown to interact with residues 16-22 on PLB. Fluorescence resonance
energy transfer (FRET) experiments suggested that HAX-1 decreases PLB pentamer
stability, increasing the pool of PLB monomers available to inhibit SERCA. This model
was compatible with FRET measurements of the SERCA/PLB regulatory complex showing
increased binding of PLB to SERCA (Vafiadaki, Arvanitis et al. 2009). The exact
mechanism by which HAX-1 alters SERCA activity has not been resolved. It is possible
that HAX-1 regulates SERCA by stabilizing or destabilizing SERCA homo-oligomers, thus
altering the functional cooperativity. It would be prudent to determine whether this
protein has a role in SERCA homo-oligomerization.
Importance of SERCA
The role of calcium handling in cardiovascular disease is evident. In addition to
the data presented above, SERCA has been implicated in other diseases as well.
Artemisinins are potent anti-malarial drugs used in treating multi-drug resistant malaria.
Recently, they were determined to target PfATP6, a SERCA orthologue found in
parasites that transmit malaria (Eckstein-Ludwig, Webb et al. 2003). Calcium is an
important part of cell survival and growth and has been implicated in many signaling
pathways (Yano, Tokumitsu et al. 1998, Apati, Janossy et al. 2003). Consequently, SERCA
has been implicated in some forms of cancer and is being considered as a therapeutic
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target (Denmeade, Jakobsen et al. 2003, Dubois, Vanden Abeele et al. 2013, Roti,
Carlton et al. 2013). A greater understanding of the SERCA/PLB regulatory complex and
mechanisms of activity may provide new interventions for disease.
In the present study we set out to examine SERCA homo-oligomerization and
regulation. We used photoactivatable cross-linking to investigate whether SERCA is
oligomeric in cardiac myocytes. This work was extended to AAV-293 cells in order to
quantify important parameters of structure and regulation. Using spectroscopic
approaches, we quantified the stoichiometry of the putative oligomer and determined
whether oligomerization was regulated by mechanisms known to be important
determinants of SERCA activity. Various approaches were employed to examine how
oligomerization can be pharmacologically or physically altered within the live
membrane. Lifetime measurements allowed us to resolve discrete populations within
the cell and to examine the interaction of PLB with SERCA and regulation in response to
phosphorylation of PLB. Finally, functional measurements of SERCA activity helped
provide insight into the physiological role of homo-oligomerization.

CHAPTER THREE
MATERIALS AND METHODS
A major enabling technology of the present study was the use of fluorescence
resonance energy transfer (FRET). FRET provides many distinct advantages over other
methods aimed at examining protein-protein interactions. It can be used in live cells so
that the full physiological environment is preserved. Live cells also provide easy
manipulation of physiological pathways and effectors. Beyond that, FRET techniques
provide information about protein-protein affinity, structure, concentration,
stoichiometry, quantitative measurements of distance, and identification of multiple
populations of species.
FRET is a process that describes the biophysical property of nonradiative energy
transfer between two chromophores. This requires that the emission spectrum of the
donor chromophore overlaps with the excitation spectrum of the acceptor
chromophore (Tsien 1998). If the two labels are in close proximity the excited donor will
transfer energy to the acceptor. FRET is very sensitive to distance and is most effective
when the distance between donor and acceptor fluorescent proteins is between 25 and
100 Å; the ideal range varies depending on the physical properties of the particular
donor and acceptor selected. Figure 4 illustrates the FRET signal in response to distance
changes for a CFP donor and YFP acceptor. At distances shorter than 25 Å the FRET
signal is saturated and changes in distance will not alter the apparent FRET signal. At
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Figure 4. A simulation of the dependence of FRET efficiency on fluorescent protein
separation distance (R) for cyan fluorescent protein (CFP) and yellow fluorescent protein
(YFP). The Förster distance (R0) is the distance at which FRET efficiency = 0.5.
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distances greater than 100 Å energy transfer cannot take place. This has the distinct
advantage of generally limiting measurements to short distances where protein-protein
interactions likely occur. There are many ways to measure FRET, some of which are
outlined below. Each method has its own advantages and disadvantages, but, used
together, these methods provide a substantial amount of information about the
protein-protein interaction being studied.
Molecular biology and cell culture
Canine SERCA2a was labeled with mCerulean (Cer), enhanced green fluorescent
protein (GFP), or enhanced yellow fluorescent protein (YFP). Labels were positioned at
the N-terminus, between residues 508 and 509, or at the C-terminus. Canine PLB was
labeled at the N-terminus with YFP or mCherry. Mutations were made to the PKAdependent phosphorylation site serine 16 of PLB to produce the nonphosphorylatable
(S16A) and phosphomimetic (S16E) variants. FRET standards were used as positive
controls in which Cer is fused to Venus fluorescent protein with a 5, 17, or 32 amino acid
linker (C5V, C17V, or C32V) or Cer is fused between two Venus fluorescent proteins with
linker sizes of five amino acids (VCV). All constructs were validated with nucleotide
sequencing. Constructs were expressed by transient transfection of AAV-293 cells using
the MBS mammalian transfection kit (Agilent Technologies). After 24 hours, the cells
were trypsinized for one minute and plated on glass-bottom chambered slides (Matek)
coated with poly-D-lysine. Cells were allowed to adhere to the slide for two hours
before carrying out FRET measurements.
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Progressive acceptor photobleaching
Acceptor photobleaching is a technique that utilizes irreversible selective
destruction of the acceptor chromophore through prolonged excitation. Once
destroyed, the acceptor is no longer capable of quenching the donor and, if the donor
and acceptor are at a distance capable of FRET, the donor intensity will increase. The
stoichiometry of a molecular complex can be determined from the relationship between
the donor and acceptor intensities over time. If this relationship is linear, then it
indicates the donor- and acceptor-labeled complex exists as a dimer (N = 2). However, if
this relationship is curved, then the complex exists as a higher order oligomer (N > 2)
(Kelly, Hou et al. 2008).
Acceptor photobleaching was carried out on an inverted microscope (Nikon)
equipped with a 60X oil immersion objective with a numerical aperture of 1.49. A Lumen
200 metal halide lamp (Prior) and excitation and emission filters (Semrock) were used to
selectively excite the Cer and YFP channels and collect the emission signal. Images were
collected using a back-thinned iXon 887 CCD camera (Andor Technology). Selection of
the appropriate excitation and emission filters was managed by motorized filter wheels
(Sutter Instruments). Cells were imaged every 10 seconds for 500 seconds and YFP was
selectively photobleached by exposure to YFP excitation (504/12 nm) in the time
between each image. The photobleaching power at the sample was approximately 1.59
nW/μm2. Images were analyzed in the MetaMorph software program by manual
selection of the cell fluorescence area. The average intensity values of the fluorescent
area of the cell over time were normalized to the prebleach intensity using the
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equation: F/F0 = (F-Fbg)/(F0-F0bg), where F is the fluorescence intensity, F0 is the
prebleach fluorescence intensity, and Fbg and F0bg are the background fluorescence
signals. Figure 5 shows a representative field of cells expressing Cer-SERCA and YFP-PLB
before and after the photobleaching process.
Acceptor-sensitized emission FRET
We utilized acceptor-sensitized emission FRET as a way of measuring proteinprotein affinity and structure. This method allows FRET to be calculated from images of
the donor and acceptor intensities with their respective excitation as well as a third
image that captures the acceptor emission with donor excitation. It does not require
long collection times such as needed with acceptor photobleaching. This allows a large
number of cells to be quantified in a relatively short time period. Previous studies have
shown that acceptor-sensitized FRET is consistent with other methods (Hou, Kelly et al.
2008, Kelly, Hou et al. 2008, Hou and Robia 2010).
Acceptor-sensitized FRET was performed on a Nikon inverted microscope
equipped with a 40X NA dry objective. A motorized stage surveyed 120 individual
locations and collected 150 ms exposures of the intensity of Cer emission following Cer
excitation (Cer), YFP emission following YFP excitation (YFP), and YFP emission following
Cer excitation (FRET). The 120 images for each condition were stitched together into a
single montage image. Fluorescence intensity was measured by a multi-wavelength cell
scoring application (MetaMorph). The background threshold was set to 110 counts. Cell
size criteria were limited to 9 – 19 μm in diameter. FRET efficiency was calculated using
the equation E = G/(G+4.6 x FCer) where G is an instrumental correction factor defined by
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Figure 5. Representative images of AAV-293 cells expressing Cer-SERCA and YFP-PLB
before photobleaching (pre-bleach) and after photobleaching for 10 minutes (postbleach). Note the decrease in YFP intensity and concomitant increase in Cer intensity as
the donor and acceptor are close enough for FRET.
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the equation G = FFRET – a x FYFP – d x FCer. FFRET, FYFP, and FCer are the cell average
fluorescence intensities for the FRET, YFP, and Cer channels, respectively, and G is the
FRET intensity corrected for bleed through of the donor (d) and acceptor (a) channels.
The donor bleed-through constant was calculated by imaging cells that only expressed
the donor and dividing the resulting FRET image by the donor image. The acceptor
bleed-through was similarly calculated from cells that expressed only the acceptor and
dividing the resulting FRET image by the acceptor image. The bleed through constants a
and d were determined to be 0.085 and 0.737, respectively on our experimental setup.
Each cell that expressed both Cer and YFP at a level above background threshold
was plotted as percent FRET over the range of expressed protein concentration, as
determined by the fluorescence intensity of the YFP channel (expressed in arbitrary
units). The plotted data were fit by a hyperbola using the equation: FRET=FRET max*X/(Kd
+ X) where X is the measured YFP intensity, FRETmax is the maximum FRET, and Kd is the
apparent dissociation constant of the donor- and acceptor-labeled proteins for each
other.
Fluorescence lifetime measurements
Fluorescence lifetime decays were collected using a Nikon Eclipse Ti inverted
microscope equipped with a 60X NA water immersion objective. GFP was excited using a
supercontinuum laser pulsed at a rate of 20 MHz (Fianium) and a 482/18 nm bandpass
filter (Semrock Inc.). The fluorescence emission was passed through a dual band
bandpass filter (523/610) and dichroic filter in the microscope (488/561 nm) and a 50
μm confocal pinhole. The emission was then directed through a 525/50 nm bandpass
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filter to an avalanche photodiode (Micro Photon Devices) using a dichroic beamsplitter
(565 nm, Chroma).
Fluorescence lifetime measurements were obtained from AAV-293 cells
expressing GFP-SERCA alone or GFP-SERCA with mCherry-PLB. The level of expression of
fluorescently labeled proteins in each cell was determined by using a 500 mm focal
length planoconvex lens in a flip mount to defocus the excitation beam (560/14 nm) of
the supercontinuum laser in order to excite the entire cell. The area of excitation at the
Z-position of the cell was calculated to be 30 μm in diameter (approximately the size of
one cell). The emitted fluorescence of mCherry-PLB was detected using a 640/50 nm
bandpass filter and a CCD camera (CoolSNAP K4, Photometrics). The average
fluorescence intensity of the cell (expressed in arbitrary units) was used as an index of
the protein concentration. After each image was obtained, the lens was removed from
the path and time correlated single photon counting was performed using single point
excitation and confocal detection using the avalanche photodiode. Photons were
collected until the peak of the decay reached a minimum of 104 photons.
Fluorescence decays obtained from each cell were analyzed independently by
tail fitting with a one- or two-component exponential decay from 3.5 ns using the
SymPhoTime 64 software (Picoquant Photonics). The amplitude parameter was
constrained to values between 0% and 100%. The tau parameter was compared to the
average fluorescence intensity of mCherry-PLB for each cell measured with the CCD
camera to determine the dependence of fluorescence lifetime on protein expression.
Two-component analysis of GFP-SERCA fluorescence decays was performed by fixing
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one lifetime to the donor-only tau in order to limit the number of floating parameters.
FRET efficiency (E) was calculated using the equation: E = 100 x (1-τDA/τD), where τDA is
the lifetime of the donor in the presence of acceptor and τD is the lifetime of the donoronly sample. Distance measurements were calculated from the relationship R = R 0(E-1 –
1)1/6, where R0 is the Förster distance for the GFP/mCherry pair (5.31 nm) and E is the
average FRET efficiency from the lifetime measurements, assuming a random
orientation factor (κ2 = 2/3).
Photon counting histogram (PCH) analysis
AAV-293 cells expressing GFP-SERCA were cross-linked and separated out using
SDS-PAGE as detailed below. Monomeric SERCA (135 kDa) and cross-linked SERCA (301
kDa) were excised from the polyacrylamide gel and soaked in PBS for three hours at
room temperature. Fluorescence correlation spectroscopy (FCS) was used to determine
the concentration of GFP-SERCA of the gel eluants and the samples were diluted in
order to compare equal concentrations of the eluted species in the subsequent PCH
analysis. Photon counting was performed with a PicoHarp 300 TCSPC module
(PicoQuant Photonics). FCS data were collected until the peak of the fluorescence decay
had reached 104 photons. Histograms were generated in the SymPhoTime 64 software
using a bin width of 0.2 ms and exported to Globals Software for Spectroscopy and
Images (LFD, University of California, Irvine). PCH brightness analysis was performed
using a one-photon, three dimensional Gaussian-Lorentzian model with one- or twospecies minimization.
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Co-immunoprecipitation
Co-immunoprecipitation was performed in cells expressing GFP-SERCA2a and
cMyc-SERCA2a at a molar plasmid ratio of 1:1. The cells were detached with a cell
scraper in PBS and centrifuged at 500 G for five minutes. The supernatant was aspirated
and the pellet was resuspended in cell lysis buffer containing 150 mM NaCl, 50 mM Tris,
1% Nonidet-P-40, and EDTA-free protease inhibitor cocktail at pH = 8.0. The suspended
pellet was incubated at 4 °C on a shaker for 20 minutes and then centrifuged at 13,000
G for 10 minutes at 4 °C. The supernatant was transferred to a new centrifuge tube and
incubated overnight at 4 °C with mouse anti-cMyc antibody (Clontech Laboratories, Cat.
#631206) or mouse non-specific IgG antibody (Sigma-Aldrich, Cat. # I5381). The resulting
immunocomplex was transferred to a new microcentrifuge tube containing protein-G
magnetic Dynabeads. The sample was incubated for one hour at room temperature and
then washed four times with cell lysis buffer. The final solution containing the beads was
incubated at 55 °C for 10 minutes in 1% SDS with beta-mercaptoethanol to elute the
bound protein. The resulting protein was separated out using SDS-PAGE and western
blotting.
Photoactivatable chemical cross-linking
Left ventricular cardiomyocytes were isolated from adult New Zealand white
rabbits by a core facility as previously described (Domeier, Blatter et al. 2009). All animal
protocols were approved by the Loyola University Institutional Animal Care and Use
Committee. Myocytes were permeabilized for two minutes with 100 μg/mL saponin
(Sigma-Aldrich) in a potassium-free relaxing solution containing: 100 mM NaCl, 5 mM
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MgCl2, 2 mM EGTA, 10 mM Imidazole, 4 mM ATP, and 50 mM tris(2carboxyethyl)phosphine at pH = 7.0. A complete protease inhibitor cocktail (Santa Cruz
Biotechnology) was added prior to the start of the experiment. The permeabilized
myocytes were centrifuged for 5 minutes at 500 G at 4 °C. The supernatant was
removed and replaced with potassium-free relaxing solution containing the
photoactivatable cross-linker benzophenone-4-maleimide (BPM) (Sigma-Aldrich). BPM is
a heterobifunctional cross-linker which contains a sulfhydryl-specific group and a
photoactivatable group. The pellet was resuspended and incubated for one hour at
room temperature. The suspension was then placed on ice and irradiated for 20 minutes
by a long wave ultraviolet lamp set at 365 nm (UVP). A 2X cell lysis solution (300 mM
NaCL, 100 mM Tris, 2% SDS, pH = 8.0) was added in equal volume to the suspension in
preparation for western blotting.
Protein quantification
Protein concentrations were determined from a bicinchoninic acid protein assay
(Pierce). 20 μL of sample and water were loaded in triplicate on a 96-well plate. A
standard curve was generated by using 2 mg/mL bovine serum albumin. Reagent 1 and
2 were combined as per the provided protocol and 200 μL were added to each well. The
plate was incubated at 37 °C for 30 minutes and then placed in an Epoch microplate
spectrophotometer (BioTek Epoch) to measure the absorbance at 562 nm.
Western blotting
Samples were separated on a 4-15% polyacrylamide precast gradient gel (BioRad). The separated protein was transferred to polyvinylidene difluoride membrane at
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100 V for two hours at 4 °C. The membrane was blocked in milk for one hour at room
temperature followed by incubation of the primary antibody rabbit anti-GFP (1:2000;
Life Technology), mouse anti-SERCA2 (1:2000, AbCam, Cat. # ab2817), or mouse anticMyc (1:2000, Clontech Laboratories, Cat. # 631206) overnight at 4 °C. Blots were
incubated with anti-mouse or -rabbit secondary antibodies conjugated to horseradish
peroxidase for two hours at room temperature (1:20,000 dilution). The blots were
developed using an electrochemiluminescence substrate (Perkin Elmer) and imaged
using a ChemiDoc XRS+ (Bio-Rad).
ATPase measurements
SERCA enzymatic activity was quantified in cell homogenates by
spectrophotometric measurement of the rate of NADH consumption in an enzyme
coupled activity assay. AAV-293 cells expressing SERCA and/or PLB were detached using
cold PBS and cell scraper. The cells were pelleted for 5 minutes at 4 °C and 500 G. The
supernatant was aspirated and the cell pellet was resuspended in homogenization
buffer (0.5 mM MgCl2, 10 mM Tris-HCl at pH = 7.5, and a complete protease inhibitor
cocktail). The suspension was left on ice for 5 minutes and then homogenized with 30
strokes of a Potter-Elvehjem homogenizer. An equal amount of 2X sucrose buffer (100
mM MOPS at pH = 7.0, 500 mM sucrose, and 1 Complete protease inhibitor cocktail)
was added followed by DNAse equal to 20% of the volume.
A 5X buffer was made from 0.25 M MOPS, 0.5 M KCl, 25 mM MgCl2, 5.0 mM
EGTA, pH = 7.0. This was used to make a 2X assay mix buffer consisting of 20% 5X buffer
(by volume), 0.4 mM NADH, 1.0 mM PEP, 5.0 mM ATP, 10 IU/mL LDH, 10 IU/mL PK, and
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0.00712 mg/mL calcium ionophore. A 2X sucrose buffer was made containing: 40 mM
MOPS (pH = 7.0), 0.6 M sucrose, and 2 mM NaN3 at pH = 7.0 at room temperature. A
range of 20X calcium solutions were made by combining 20 mM CaCl2 with ddH2O as
detailed in Table 1. This 20X calcium solution was diluted in water and 2X sucrose buffer
to yield a 4X calcium solution at 1X sucrose. The homogenate, 4X calcium solution, and
2X assay mix were heated to 37 °C and then combined. The absorbance at 340 nm was
read on a plate reader at 37 °C. The enzymatic reaction scheme for this protocol is
detailed in figure 6. Purified rabbit fast-twitch skeletal SR preparations were obtained as
described by Mueller et al. (Mueller, Karim et al. 2004). Purified pig cardiac SR
membrane vesicles were obtained as described by Fruen et al. (Fruen, Bardy et al.
2000). Both the skeletal and cardiac SR preparations were a gift from David D. Thomas
at the University of Minnesota.
The rate of the decrease in NADH absorbance was plotted against the calcium
concentration. The data were fit with a Hill equation of the form:
y = y0 + (Vmax – y0)(xn/(kn+xn)) where y0 is the y offset, Vmax is the maximum rate of
calcium transport, k is the calcium concentration at half maximal activity, and n is the
Hill coefficient.

39

Table 1. The necessary volumes of 20 mM CaCl2 and ddH2O to produce a 20X calcium
solution at 37 °C.
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Figure 6. A schematic representation of the enzyme-linked ATPase assay. SERCA
consumes ATP which is regenerated with pyruvate kinase and phosphoenolpyruvate
(PEP). Pyruvate is turned into lactic acid with lactate dehydrogenase, oxidizing NADH in
the process. The rate of decrease in absorbance at 340 nm is taken as an index of the
rate of ATP consumption.

CHAPTER FOUR
RESULTS
SERCA homo-oligomerization
Previous studies have shown that SERCA is capable of forming homo-oligomers
in reconstituted lipid bilayers. To determine whether SERCA is oligomeric in live cells we
performed co-immunoprecipitation in AAV-293 cells transiently co-transfected with
GFP-SERCA and cMyc-SERCA. We used a buffer containing Nonidet P-40, which has been
previously shown to preserve ER membrane protein interactions with SERCA and other
regulatory partners (Han, Cai et al. 2011). Immunoprecipitation with anti-cMyc pulled
down GFP-SERCA (Figure 7A). A control IgG antibody did not pull down either cMyc- or
GFP-labeled SERCA, suggesting that SERCA protomers interact with each other.
As an alternative approach, we investigated the interaction of SERCA protomers
in the biosynthetic membranes of ventricular cells. We treated isolated rabbit cardiac
left ventricular (LV) myocytes with saponin to selectively permeabilize the sarcolemma
and performed photoactivatable cross-linking with BPM. BPM is a heterobifunctional
cross-linker with a thiol-specific maleimide group and a photoactivatable benzophenone
group capable of reacting with alpha carbons. This cross-linker is advantageous because
the maleimide chemistry enables targeting of SERCA, which is estimated to contain
more than 50% of the reactive thiols in the SR membrane by content (Viner, Williams et
al. 1999). Furthermore, this benzophenone group does not depend on prior
41
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Figure 7. Oligomerization of SERCA probed with co-immunoprecipitation (co-IP) and
cross-linking. A) Co-IP of GFP-SERCA with Myc-SERCA. B) Western blot analysis of rabbit
LV myocytes. Increasing concentrations of benzophenone-4-maleimide (BPM) decreased
the amount of monomeric SERCA (band 1) and gave rise to two additional bands (Band 2
and Band 3). C) Pretreatment of myocytes with 50 nM isoproterenol (iso) did not
appreciably alter the SERCA electrophoretic pattern. D-F) Quantification of Bands 1, 2,
and 3 relative to total SERCA. Values are mean ± SD from N = 3 independent blots.
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identification of the binding interface or mutation of specific residues for reactivity and
successful cross-linking.
Western blots of the cross-linked LV myocytes were probed with a SERCA2
primary antibody, revealing a single band at approximately 99 kDa (Figure 7B, Band 1) in
keeping with the molecular weight of the SERCA monomer. Increasing concentrations of
BPM caused a decrease in the relative amount of the SERCA monomer (Figure 7D) and
yielded a new prominent band at 230 kDa (Figure 7B, Band 2). At the highest BPM
concentrations (>100 μM) we observed a third band at 315 kDa (Figure 7B, Band 3). The
contributions of these cross-linked species are quantified in figures 7D-F.
Previous studies have suggested that phosphorylation of PLB at serine 16 may
play an essential role in SERCA homo-oligomer formation. However, we did not observe
a significant change in cross-linking after treatment of myocytes with 50 nM betaadrenergic agonist isoproterenol (iso) (Figure 7C). The data suggest that PLB
phosphorylation does not alter BPM cross-linking of SERCA. The relative amount of the
SERCA monomer increased with pre-incubation of increasing amounts of the detergent
n-dodecylphosphocholine (DPC) (Figure 8A & B). It was noteworthy that high molecular
weight species were still produced even after with pre-solubilization of apparent SERCA
dimers with 1% DPC, suggesting a robust oligomeric interaction was present before the
addition and activation of cross-linker. This may also indicate that previous studies using
detergent-solubilized SERCA may not have contained 100% monomers.
We attempted to identify the reactive cysteine on SERCA that may be
responsible for cross-linking. Canine SERCA contains 26 cysteines. 10 of these are
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Figure 8. Detergent solubilization of SERCA A) Pre-incubation with the detergent ndodecylphosphocholine (DPC) in 300 μM BPM increased the relative amount of
monomeric SERCA (Band 1). B) Quantification of A.
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located in the TM domain and are likely inaccessible. Additionally, some of the
cysteines positioned in the cytosolic domain form internal disulfide bridges and would
not be reactive (Sharov, Dremina et al. 2006). We selected four reactive cysteines for
mutation: C364, C498, C636, and C674. Individual mutations of these residues did not
abrogate the cross-linking reaction, suggesting that the cross-linked species observed by
western blotting are not a result of BPM interaction with these residues. This indicates
that a different cysteine residue may be responsible for the cross-link or the cross-link
may form from modification of another binding partner.
To determine whether the high molecular weight bands seen by cross-linking
contained multiple SERCA protomers or a single SERCA protomer cross-linked to another
binding partner (Arvanitis, Vafiadaki et al. 2007, Vafiadaki, Sanoudou et al. 2007, Zhao,
Li et al. 2015), we performed cross-linking of GFP-SERCA heterologously expressed in
AAV-293 cells. Western blotting of the non cross-linked control sample showed GFPSERCA monomer at a molecular weight of 135 kDa (figure 9A). This +35 kDa shift in
mobility compared to the unlabeled SERCA seen in figure 7B is consistent with the
increase in molecular weight corresponding to attachment of a single GFP of
approximately 30 kDa (Prendergast and Mann 1978). The cross-linked GFP-SERCA
produced a second band at 301 kDa. We noted that this band was shifted by a value of
+71 kDa, approximately equal to the molecular weight of two GFP molecules. The third
band was not evident by western blot and is possibly indistinguishable from the second
band or perhaps too large to enter the gel.
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Figure 9. Brightness analysis. A) A representative western blot of GFP-SERCA crosslinked in AAV-293 cells. The areas in blue demarcate the molecular weight range where
samples were extracted from polyacrylamide gels. B) Photon counting histograms (PCH)
for the two extracted fractions. Fits (shown in gray) were generated from the Globals for
Spectroscopy software. C) Brightness measurements from PCH analysis of GFP-SERCA
isolated from low molecular weight (black) and high molecular weight (red) fractions
revealed an increased molecular brightness (ε) for the high molecular weight species.
Molecular brightness values are mean ± SD from N = 3 individual gel slices (unpaired ttest, p < 0.01). D) Soluble GFP brightness measurements in sodium dodecyl sulfate
(mean ± SD).
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The two GFP-SERCA SDS-PAGE bands were excised and eluted from
polyacrylamide gels by incubation in PBS. The concentration of GFP-labeled SERCA was
quantified by fluctuation correlation spectroscopy (FCS). FCS was used to generate an
autocorrelation function for GFP-excited sample. The Y-axis intercept of the function
(G(0)) is directly dependent on concentration of the sample. The G(0) values were then
used to dilute the two GFP-SERCA samples down to equal concentrations. A photon
counting histogram (PCH) was generated from the FCS data (Figure 9B) and used to
calculate brightness. Brightness measurements revealed that the 135 kDa section of the
gel containing monomeric GFP-SERCA had a molecular brightness of 2338 ± 76 counts
per second per molecule (cpsm) while the cross-linked species (301 kDa) had a
molecular brightness of 2832 ± 35 cpsm (mean ± SD) (figure 9C).
Notably, the apparent molecular brightness of the cross-linked band was not
increased 2-fold. Many factors may contribute to the apparently decreased brightness
of the cross-linked species: A) BPM cross-linking may covalently modify some GFP and
decrease or eliminate its fluorescence. B) UV exposure (for BPM activation)
photobleaches some GFP molecules. C) Competition from endogenous SERCA creates
some complexes where only a single SERCA has a GFP tag. D) Background fluorescence
adds to the apparent molecular brightness of both the high and low molecular weight
samples. E) SDS detergent presumably denatures a large number of the GFP molecules.
All of these factors are expected to reduce the apparent difference between the low
and the high molecular weight bands. Qualitatively, the data are taken to indicate
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increased molecular brightness of the high molecular weight species consistent with an
oligomeric complex of several GFP-SERCA protomers.
To confirm that SDS itself does not alter GFP brightness, we performed
brightness measurements on purified soluble GFP protein. Brightness slightly decreased
with increasing concentrations of SDS, but was not significant (Figure 9D). The values
obtained compared favorably to the brightness measurements from GFP-SERCA.
Previous studies have shown that soluble GFP may have a slightly greater brightness
than GFP attached to proteins, as the latter may be quenched in part by the bound
protein (Nils 2010).
Oligomeric structure and regulation
We next sought to examine the quaternary structure and regulation of SERCA
homo-oligomers in live cells using FRET techniques. To determine if attachment of
fluorescent proteins alters SERCA function we performed ATPase assays on microsomes
expressing SERCA. Cer-SERCA in the absence of PLB displayed calcium-dependent
ATPase activity with sensitivity similar to skeletal SERCA1a (figure 10). Co-expression
with YFP-PLB caused a rightward shift in this relationship; the magnitude of this change
was similar to previous reports (Mueller, Karim et al. 2004). We also noted that
expression of fluorescently-labeled SERCA and PLB targeted and localized to the ER/SR
membrane correctly.
We made FRET measurements from Cer-SERCA to SERCA labeled with YFP at the
N-terminus (“N”), inserted before residue 509 (“509”), or fused to the C-terminus (“C) as
diagrammed in figure 11A of a SERCA crystal structure: PDB 4KYT
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Figure 10. Calcium ATPase measurements for skeletal SR microsomes (black) prepared
from rabbit fast twitch muscle and microsomes prepared from AAV-293 cells expressing
Cer-SERCA (red) or Cer-SERCA and YFP-PLB (blue).
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Figure 11. FRET labeling strategy. A) FRET was measured from the N-terminus of CerSERCA to another SERCA labeled with YFP at either the N-terminus, between amino
acids 508 and 509, or at the C-terminus. B) All three acceptor-labeled positions
produced FRET. The control FRET was measured using Cer-SERCA and non-fusion YFP.
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(Akin, Hurley et al. 2013). We observed FRET for all labeled positions (figure 11B);
however, these values are averaged from many cells and so we could not infer relative
positions of the different labeling sites. We selected the N-terminal labeling strategy for
a more detailed analysis of the SERCA-SERCA interaction. Figure 12 shows the FRET
values obtained from individual cells (dark gray) plotted as a function of whole-cell
average fluorescence intensity, taken as an index of protein concentration. We used cotransfection of Cer-SERCA and untethered YFP as a negative control (light gray). For
clarity, the data were pooled and the values are superimposed with error bars
representing SEM. FRET efficiency increased with increasing protein concentration and
this relationship was well-described by a hyperbolic fit (black line), yielding two
important parameters, the apparent dissociation constant (Kd) and maximum FRET
(FRETmax). These two parameters are quantified as indices of the Cer-YFP separation
distance and the complex binding affinity, respectively.
FRETmax and Kd were not significantly different in the absence or presence of PLB
(figure 13). Activation of the PKA pathway by application of 100 μM forskolin (an
activator of adenylate cyclase) did not alter FRETmax or Kd, even with blockade of
phosphatase activity with 100 μM 3-isobutyl-1-methylxanthine (“+PLB+F+I”), consistent
with our chemical cross-linking measurements made in myocytes following stimulation
with isoproterenol (figure 7C). We employed a monomeric mutant super-inhibitory
phospholamban containing a triple cysteine to serine mutation (C36S/C41S/C46S) in
order to test whether PLB oligomeric state altered SERCA homo-dimerization. We
detected no significant effect on SERCA-SERCA FRETmax or Kd even with activation of the
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Figure 12. Protein concentration dependence of FRET from Cer-SERCA2a to YFPSERCA2a (N) (black) or negative control Cer-SERCA2a to non-fusion YFP (red). Individual
cells are shown in gray, with pooled data (mean ±SEM) in red or black. Data were
modeled with a hyperbolic fit (lines). Maximum FRET (FRETmax) and the apparent
dissociation constant (Kd) are calculated from the fit.
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Figure 13. Apparent dissociation constants (Kd) and maximum FRET (FRETmax) values
calculated from the hyperbolic fits of FRET data in the absence (-PLB) or presence of
phospholamban (+PLBwt). Application of 100 μM forskolin and 100 μM 3-isobutyl-1methylxanthine (+PLB+F+I) did not alter the apparent affinity (Kd) of the dimer. A more
monomeric form of PLB with three cysteines mutated to serine (SSS) did not alter the
SERCA oligomer, even with application of forskolin and IBMX. Coexpression with nonphosphorylatable (+PLB-S16A) or phosphomimetic (+PLB-S16E) PLB mutants had no
appreciable effect. Alterations to calcium (2 mM) or ATP (4 mM) did not elicit any
changes. Mean ± SEM, N = 3 independent experiments (no statistically significant
differences between groups by one-way ANOVA).
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PKA pathway. Mutations to PLB at serine 16 to mimic (S16E) or prevent (S16A)
phosphorylation also had no effect on these two parameters. Thus, the present data are
not consistent with previous studies that indicated that PLB serine 16 phosphorylation
altered SERCA homo-oligomerization (Negash, Chen et al. 1996).
Previous studies have suggested that oligomerization may occur only during
specific catalytic transitions in the ATPase cycle (Andersen and Vilsen 1985, Akin and
Jones 2012). This may be a mechanism driven by binding and unbinding of homooligomers. To investigate whether oligomerization is affected by SERCA conformational
poise we measured FRET in cells permeabilized with saponin and bathed in solutions of
defined composition. We did not observe any significant changes to FRETmax or Kd when
calcium and ATP were removed or when calcium (2 mM) and/or ATP (4 mM) were
present (figure 13). These results suggest that SERCA conformational poise does not
alter SERCA homo-oligomeric structure or affinity, such as during active cycling.
Previous studies have indicated that oligomerization may be enhanced by
inhibitors such as thapsigargin (TG) and melittin as part of a regulatory mechanism
(Mersol, Kutchai et al. 1995, Voss, Mahaney et al. 1995). We used a 2-color SERCA
construct comprised of a donor fluorescent protein attached to the N-terminus (Adomain) and an acceptor fluorescent protein positioned between amino acids 508 and
509 (N-domain) (figure 14A) to determine if TG induces structural changes in the pump.
Titration of TG reduced FRET by approximately 10%, indicating separation of the A- and
N-domain and a more “open” conformation following binding by TG (figure 14B). This
was in agreement with previous data from our laboratory
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Figure 14. Effects of inhibitors on SERCA oligomerization. A) The labeling strategy for “2color” SERCA consisting of a Cer donor attached to the N-terminus (A-domain) and a YFP
acceptor inserted between amino acids 508 and 509 (N-domain). Generated from the
SERCA crystal structure 1IWO (Toyoshima and Nomura 2002). B) Titration of
thapsigargin decreased the FRET between the N- and A-domain, indicating an increase
in separation distance (Hill fit shown in red). C) Application of 10 μM thapsigargin to
AAV-293 cells expressing Cer-SERCA and YFP-SERCA did not alter FRETmax or Kd. D)
Treatment with 50 μg/mL saponin and/or 250 μM melittin did not alter FRET (mean ±
SD).
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(Hou, Hu et al. 2012, Pallikkuth, Blackwell et al. 2013). Despite this large conformational
change, we did not detect any alterations to the SERCA homo-dimer FRETmax or Kd
(figure 14C). We also examined the effect of melittin (an active component in bee
venom) on homo-dimerization. We found that melittin disrupted the cell membrane
integrity; however the average FRET was not significantly altered by application of 250
μM melittin (figure 14D).
Previous work has identified HAX-1 as a regulator of the SERCA/PLB regulatory
complex through stabilization of the PLB monomer. FRET experiments showed that
SERCA/PLB FRET is increased in the presence of HAX-1 while PLB pentamer FRET is
decreased (Vafiadaki, Arvanitis et al. 2009). We measured SERCA oligomer FRET in the
absence and presence of HAX-1, but found no difference in the FRETmax and Kd
parameters (figure 15A). We observed, however, that HAX-1 appeared to increase CerSERCA and YFP-SERCA expression. To test whether HAX-1 increased expression of SERCA
or PLB, we co-transfected HEK cells with HAX-1 and SERCA or PLB. Increasing molar
ratios of HAX-1 resulted in dramatically increased protein expression levels of SERCA or
PLB (figure 15B). The altered expression, however, did not alter the Kd or FRETmax
parameters, suggesting that HAX-1 does not regulate SERCA-SERCA affinity or structure.
To determine whether our measured SERCA-SERCA FRET was due to specific
protein-protein interactions, rather than a consequence of non-specific protein
crowding in the membrane, we measured Cer-SERCA/YFP-SERCA FRET in the presence
of a third species of unlabeled SERCA (figure 16A). Unlabeled SERCA should act as a
competitor if specific protein-protein interactions contribute to the detected FRET
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Figure 15. Effect of HAX-1 on oligomerization. A) Co-expression of HAX-1 with CerSERCA and YFP-SERCA did not alter FRETmax or Kd, however, an apparent increase in
protein expression with HAX-1 was noted. B) This was further examined over a range of
molar ratios of HAX-1 relative to YFP-PLB (mean ± SD).

58

Figure 16. FRET competition assay. A) FRET from Cer-SERCA and YFP-SERCA was reduced
by coexpression of non-fluorescent SERCA. Values reflect the molar ratio of
competitor:YFP-SERCA. B) FRETmax was decreased by competition with non-fluorescent
SERCA (black) but not by PLB (blue). Hyperbolic fit shown in red.
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signal. The transfection ratio of Cer-SERCA to YFP-SERCA was kept at a constant molar
ratio of 1:5 while increasing molar ratios of unlabeled SERCA were co-transfected.
Increasing the molar ratio of unlabeled SERCA relative to YFP-SERCA caused a
progressive decrease in FRETmax (figure 16B, black data points). This reduction in FRETmax
was well described by a hyperbola (red fit), consistent with simple competition of
unlabeled SERCA for the fluorescently labeled SERCA protomers in the oligomeric
complex. The data suggest that the FRET observed here is due to a specific interaction
between SERCA molecules. The residual FRET remaining at the highest competitor:YFP
ratio tested was 3.5%, and is taken as an estimate of non-specific FRET between noninteracting donors and acceptors. Notably, using PLB as a competitor did not alter the
measured SERCA-SERCA FRET at any ratio tested (figure 16B, blue data points),
consistent with the experiment shown in figure 13. We conclude that the presence or
absence of PLB did not alter the constitutive oligomerization of SERCA under the present
experimental conditions.
We further sought to disrupt our FRET signal by titration of anti-SERCA
antibodies, as this would provide a useful tool for separating SERCA homo-oligomers in
the membrane. AAV-293 cells expressing Cer-SERCA and YFP-SERCA were subjected to
permeabilization with saponin and incubation with anti-SERCA2 IID8 antibody (IID8,
AbCam). Incubation of this antibody did not alter FRET even after incubation for nearly
four hours (figure 17). We cannot draw a conclusion about the region of binding, as the
exact sequence identity of the epitope is unreported. We also utilized crude test bleeds
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Figure 17. FRETmax measurements of AAV-293 cells expressing Cer-SERCA and YFPSERCA. Cells were treated with saponin in the presence of increasing concentrations of
anti-SERCA2 (IID8) antibody and incubated at room temperature for the indicated
period of time (mean ± SD from N = 3 experiments per treatment).
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from rabbit sera targeting various peptides within the P-domain of SERCA. These were
raised against the following peptide sequences:
n-CATEQERTPLQQKLDEF
n-CLGTRRMAKKNAIVRSLP
n-YNEAKGVYEKVGEAT
n-CPDLDIMNKPPRNPKEPL
n-DPPRIEVASSVKL
n-SLLRMPPWENIWLVGSI
Incubation with sera from these rabbits did not alter the oligomeric FRET, suggesting
that the P-domain is not involved in homo-oligomerization.
SERCA homo-oligomeric stoichiometry
To determine the oligomeric stoichiometry of SERCA, we performed progressive
acceptor photobleaching with AAV-293 cells transiently expressing Cer-SERCA and YFPSERCA or Cer-SERCA and untethered YFP. Figure 18A shows the progressive decrease in
YFP-SERCA emission (black) as YFP is selectively photobleached. This occurred with a
concomitant increase in Cer-SERCA emission (blue) as the donor is close enough for
FRET. Figure 18B shows the relationship between the changes in donor and acceptor
intensities. The relationship was linear for Cer-SERCA + YFP-SERCA (black). The Cer
intensity did not increase for a negative control expressing Cer-SERCA + untethered-YFP,
demonstrating that this donor/acceptor pair is not interacting (red). The stoichiometry
of the donor-acceptor complex is reflected in a comparison of the donor and
fluorescence intensities (Li, Reddy et al. 1999). As an example, figure 19A shows that Cer
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Figure 18. Acceptor photobleaching of the SERCA oligomer. A) Progressive acceptor
photobleaching of YFP-SERCA (black) resulted in increased Cer-SERCA fluorescence
(blue), indicating FRET. Mean ± SEM, N = 28 cells total from 3 independent experiments.
B) Photobleaching of the SERCA homo-oligomer resulted in a linear increase in Cer
intensity with decreasing YFP intensity (black). No increase in Cer-SERCA intensity was
observed for non-fusion control (red).
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Figure 19. The relationship of donor/acceptor fluorescence intensities during the
process of photobleaching for a construct comprising A) one acceptor and one donor
(C32V) or B) a construct comprising two acceptors and one donor (VCV). C) This
relationship was also plotted for Cer-PLB and YFP-PLB, a well-known pentameric
oligomer. Mean ± SD, N = 12 cells. Lines connect the first and last data points.
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fluorescence (plotted on the ordinate) increases linearly with the decrease in Venus
acceptor fluorescence (plotted on the abscissa, decreasing from right to left over time)
for a control construct (C32V) expressing a tethered donor and acceptor in a
stoichiometry of 1:1. In contrast, a construct comprising a donor tethered to two
acceptors (VCV) displayed significant curvature (figure 19B), since FRET persists after
ablation of a single acceptor, and donor brightness only fully increases late in the
photobleaching process when the last acceptors are photobleached. We observed
similar curvature with FRET between Cer-PLB and YFP-PLB protomers in a pentameric
complex (figure 19C). The linear relationship for the SERCA homo-oligomer observed in
figure 18B is consistent with a single acceptor in the oligomeric complex, suggesting that
SERCA forms homo-dimers. This relationship was linear over a wide range of protein
concentrations, indicating that this is the predominant oligomeric state. Photobleaching
did not provide evidence for formation of higher order oligomers or aggregates even at
the highest protein concentrations.
PLB interaction with SERCA
The above results suggest that PLB does not modulate the physical interaction
between SERCA protomers. We set out to determine whether PLB can interact with
SERCA homo-dimers or whether PLB interacts with a separate pool of monomeric
SERCA. Figure 20A shows co-localization of Cer-SERCA and YFP-PLB in AAV-293 cells.
Acceptor-sensitized FRET measurements of the complex showed a protein-dependent
binding that saturated at approximately 25% FRET (figure 20B). Acceptor
photobleaching revealed a linear donor:acceptor relationship consistent with a single

65

Figure 20. FRET measurements of the SERCA/PLB regulatory complex. A) Co-expression
of Cer-SERCA2a and YFP-PLB in AAV-293 cells. B) Acceptor-sensitized FRET
measurements of the regulatory complex. Hyperbolic fit shown in red. C) Acceptor
photobleaching of the regulatory complex, indicating the presence of a single acceptor
(YFP-PLB). Blue line connects the first and last data points. Data are shown as mean ±
SD.
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YFP-PLB acceptor in the complex (figure 20C), but this assay cannot rule out the
possibility of multiple Cer donors in the complex. In theory, one could swap the
fluorophores and perform FRET from Cer-PLB to YFP-SERCA to determine if the inverse
FRET experiment also shows a linear relationship (as in a 1:1 hetero-dimer) or a curved
relationship consistent with multiple SERCA protomers in the regulatory complex.
However, this is impractical for these proteins as PLB also avidly forms homopentamers, so most Cer-PLB donors would not participate in FRET, complicating the
analysis. As an alternative, we probed the stoichiometry of the SERCA-PLB complex with
fluorescence lifetime analysis, which can reveal subpopulations of donors with different
FRET efficiencies. Figure 21A depicts the labeling strategy, with a GFP donor fused to the
N-terminus of SERCA and an mCherry acceptor fused to the N-terminus of PLB. The
crystal structure of the regulatory complex is taken from Akin et al. and did not reveal
the PLB cytoplasmic domain (Akin, Hurley et al. 2013). As such, the actual position of the
PLB N-terminus and mCherry fluorescent protein tag are unknown.
Figure 21B shows the fluorescence decay of GFP-SERCA in the absence (black) or
presence of mCherry-PLB (red). The decrease in the GFP fluorescence lifetime in the
presence of mCherry-PLB (red) is consistent with FRET from GFP to mCherry. Decays
were obtained from 99 cells and analyzed by fitting with a single component
exponential decay. The fluorescence lifetime of GFP-SERCA alone (τD) was 2.56 ± 0.02
ns. The fluorescence lifetime (τDA) of GFP-SERCA decreased with increasing mCherry-PLB
protein expression to a minimum value (figure 22A). FRET was quantified according to
the relationship FRET = 100 x (1 - τDA/τD) where τD is measured from cells expressing
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Figure 21. SERCA/PLB regulatory complex fluorescence lifetime measurements. A)
Labeling strategy for FRET from GFP-SERCA (grey) to mCherry-PLB (red). B)
Representative fluorescence decays of GFP-SERCA in the absence (black) or presence of
mCherry-PLB (red). The decay was shortened by coexpression of mCherry-PLB,
indicating FRET. Exponential tail fits are shown in gray.
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Figure 22. Fluorescence lifetime fitting. A) A single component exponential fit of the
fluorescence lifetime shows a decrease in tau (τ) with increasing protein expression.
Each point represents a measurement from an individual cell. N = 99 individual cells.
Hyperbolic fit shown in red. B) FRET (calculated from data in A) increased with protein
expression. Hyperbolic fit shown in red. C) Reduced chi-squared (χ2) values for 1component fits worsened as protein expression increased. Reduced χ2 was improved for
a two-component fit. Shown with linear fits. D) Average Reduced χ2 values obtained
from fitting the fluorescence decay to a 1-, 2-, or 3-component exponential decay.
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GFP-SERCA only. Figure 22B shows that FRET increased with acceptor expression in a
hyperbolic relationship to a maximum of 22.2% FRET, a value that is in harmony with
the acceptor-sensitized FRET measurements above (figure 20B) and previous steadystate FRET measurements from our lab (Hou and Robia 2010, Bidwell, Blackwell et al.
2011).
We observed that the single component exponential decay goodness of fit
(reduced χ2) became progressively worse as the level of protein expression increased
(figure 22C, black), suggesting that a single species model was a poor description of the
complex at higher protein expression levels. Reduced χ2 was significantly improved by a
two component exponential model, which was a good description of the data over a
wide range of concentrations (figure 22C, red). Fitting to a third component did not
improve χ2 (figure 22D). Fit residuals for one- and two-component models show that the
GFP-SERCA alone was sufficiently described by a one-component model, but GFP-SERCA
in the presence of mCherry-PLB was effectively described only by a two-component
model (figure 23). Interestingly, the two-component exponential fit yielded a long
lifetime (τL) of 2.48 ± 0.09 ns that was very similar to the GFP-SERCA only lifetime of 2.56
± 0.02 ns and a short lifetime (τS) that averaged 1.37 ± 0.09 ns. The data are consistent
with the existence of a sub-population of high FRET donors (τS) and another
subpopulation of non-FRET donors (τL). Figure 24A is a cell-by-cell measurement of the
short lifetime (τS) component. We calculated FRET from the high FRET donors (τS) over
the range in protein expression and found that the values for this population did not
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Figure 23. Representative residual plots for 1- or 2- component exponential models of
the fluorescence decay for GFP-SERCA alone (black) or in the presence of mCherry-PLB
(red).
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display protein concentration dependence as observed in the one-species exponential
model (figure 24B).
Figure 24C shows the FRETmax value obtained from the 1-species model and the
two populations obtained from the 2-species model. The average FRET efficiency of the
high FRET population (Pop. 2) was 46.3 ± 3.9%. This corresponds to an apparent probe
separation distance of 54 Å. Interestingly, the present estimate of SERCA-PLB FRET
efficiency is nearly twice that determined from acceptor-sensitized FRET measurements.
Our previous steady state measurements of the SERCA-PLB regulatory complex (which
cannot distinguish subpopulations of donors) yielded distance estimates of 10 Å longer
than the present time-resolved quantification. Previous measurements thus
overestimated the apparent separation distance between the N-terminus of SERCA and
the cytosolic domain of PLB; these two domains are closer than we previously reported.
Two-component fitting also revealed the relative proportion of the high and low
FRET populations. As expected, the percentage of donors with short lifetimes (high
FRET) increased with protein expression at the expense of the long lifetime (non-FRET)
species. However, it is noteworthy that the percentage of high FRET donors approached
but did not exceed 50% of the total (figure 24D). Thus, the numbers of high FRET and
non-FRET donors converged to approximately equal size populations. This phenomenon
may be explained by a model in which a single SERCA protomer undergoes FRET with
PLB while a second bound SERCA protomer does not. At low levels of protein expression
most SERCA protomers are likely not engaged in dimerization, thus the non-FRET
population (τL) dominates. As protein expression increases, the SERCA protomers are
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Figure 24. Bi-exponential decay fitting. A) The short lifetime values from 2-component
exponential decays were consistent across a large range of protein expression levels. B)
The short lifetime values were used to calculate FRET, which remained constant with
increasing protein expression. C) The FRETmax value calculated from the 1-component
FRET curve in figure 22 and the FRET values for the long lifetime (Population 1) and
short lifetime (Population 2) species. D) The relative contributions (amplitude) of the
short and long lifetimes.
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able to “find” each other, thus producing a FRETing SERCA and a non-FRETing SERCA
bound to PLB in a 2:1 stoichiometry. At saturated binding this would indicate equal
contributions from the two SERCA populations.
To determine whether phosphorylation of PLB alters interaction with SERCA, we
measured fluorescence lifetime in AAV-293 cells co-transfected with Cer-SERCA and
YFP-PLB containing either the S16A (non-phosphorylatable) or S16E (phosphomimetic)
mutations. Fluorescence lifetime imaging microscopy showed a homogenous
distribution of the measured lifetime, suggesting that there are not distinct subpopulations of molecules with different lifetimes at the optical resolution of our
microscope (figure 25A). The whole-cell average FRET from Cer-SERCA to YFP-PLB-S16A
measured using fluorescence lifetime was 27.1%, which was in agreement with previous
ensemble measurements. We noted again, however, that both S16A and S16E
fluorescence decays were better described by a bi-exponential model, yielding a nonFRET population (Pop. 1) and a high-FRET-population (Pop. 2). This suggests that nonphosphorylated and phosphorylated PLB both remain bound to the SERCA homo-dimer.
The average FRET for population 2 was 44.7 % ±6.15 for non-phosphorylatable PLB and
32.7 % ±3.51 for phosphomimetic PLB (Figure 25B). The average amplitudes of the low
FRET and high FRET populations were 66.9% and 33.1% respectively for PLB-S16A and
52.5% and 47.5% respectively for PLB-S16E. We noted that FRET decreased from 44.7%
to 32.7% upon phosphorylation. The magnitude of this change was twice what we
previously reported from whole cell FRET measurements (Hou, Kelly et al. 2008),
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Figure 25. Lifetime measurements with PLB phosphorylation. A) Fluorescence lifetime
images in AAV-293 cells expressing donor-labeled Cer-SERCA alone or Cer- SERCA with
YFP-PLB-S16A. Note that the color-scale in these images represents the fluorescence
lifetime (in nanoseconds) and not the color of the emitted light. B) FRET was calculated
from 2-component exponential decays as in figure 23 for Cer-SERCA in the presence of
YFP-PLB-S16A (non-phosphorylatable) or YFP-PLB-S16E (phosphomimetic). Mean ± SD, N
= 12 cells, unpaired t-test, p < 0.01.
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suggesting that phosphorylation of PLB moves the cytosolic domain more than
previously thought.
SERCA function
To examine the functional effects of SERCA in the presence of PLB, we received
purified skeletal SR from rabbit fast twitch muscle and cardiac SR from pig hearts as a
gift from Dr. David D. Thomas. We performed ATPase assays on the preparations and
observed a characteristic rightward shift in the calcium sensitivity for PLB-containing
cardiac SERCA (figure 26A). We noted, however, that the Hill coefficient for
cooperativity of activation by calcium was increased for the cardiac tissue (nH = 2.64)
relative to the skeletal tissue (nH = 1.55), suggesting that an additional cooperative
mechanism may be present with PLB.
To investigate the functional coupling of SERCA we mutated the aspartic acid
residue responsible for formation of the phosphoenzyme intermediate to alanine
(D351A). This mutant has been previously characterized as a catalytically inactive
enzyme that is still capable of binding calcium (Akin, Chen et al. 2010). Co-expression of
wild type (wt) SERCA with mutant SERCA would be predicted to alter enzyme activity if
there is a functional coupling mechanism present that relies on ATPase activity of both
paired protomers. We expressed equal amounts of wt and D351A SERCA in molar ratios
of 1:1 with PLB-S16A or PLB-S16E in AAV-293 cells and prepared microsomes.
Measurements of the ATPase activity showed calcium sensitivity with a rightward shift
for the non-phosphorylatable PLB-S16A (figure 26B). We also noted that at saturating
calcium (pCa = 5.0) the sample with S16E appeared to have a larger Vmax, but this was
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Figure 26. Calcium-dependent ATPase measurements. A) Normalized ATPase
measurements for microsomes purified from skeletal SR from rabbit fast twitch muscle
and cardiac SR from pig hearts. Data points are the mean from N = 3. Hill fits shown as
lines. B) ATPase activity from microsomes transfected with equal amounts of wild type
and D351A SERCA in a 1:1 molar ratio with PLB-S16A or PLB-S16E. Untransfected cells
are shown for comparison. Data points are the mean from N = 3. Hill fits shown as lines.
C) Vmax from the data in (B) was calculated by subtracting the untransfected ATPase
activity from the transfected activity at pCa = 5.0. Mean ± SD, N = 3, unpaired t-test, p =
0.11. D) Vmax measurements for microsomes transfected with equal amounts of wild
type and D351A SERCA without PLB or in a 1:5 molar ratio with PLB-S16A or PLB-S16E. N
= 72 for each treatment.
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not significant (figure 26C). However, these samples only expressed PLB at a 1:1 ratio
with SERCA. We hypothesized that more PLB might be necessary to observe a full
functional effect. We repeated ATPase measurements in microsomes expressing wt and
D351A SERCA in a 1:5 ratio with PLB. Measurements at saturating calcium (pCa = 5.0)
showed similar Vmax values for SERCA in the absence or presence of nonphosphorylatable (S16A) PLB. This suggests that functional coupling is not modulated by
PLB binding or unbinding. However, SERCA in the presence of phosphomimetic (S16E)
PLB showed a marked increase in Vmax, indicating that a functional coupling mechanism
may be present that is altered by phosphorylation of PLB (figure 26D). Specifically, this
functional mechanism that alters Vmax is distinct from the physical dimerization
observed. That is, dimerization by itself does not alter Vmax unless phosphorylation of
PLB is engaged.

CHAPTER FIVE
DISCUSSION
Diverse experimental approaches have provided evidence for SERCA homooligomerization (Vanderkooi, Ierokomas et al. 1977, Chamberlain, Berenski et al. 1983).
Previous studies have provided various estimates of the stoichiometry of the SERCA
oligomeric complex, with evidence supporting dimers (Negash, Chen et al. 1996, Yao,
Chen et al. 2001, Mahaney, Albers et al. 2005, Chen, Yao et al. 2009), trimers (Mahaney,
Thomas et al. 2008), or higher order oligomers (Voss, Birmachu et al. 1991, Mersol,
Kutchai et al. 1995, Voss, Mahaney et al. 1995). The present results are consistent with a
SERCA homo-dimer, as we observe a linear increase in donor fluorescence with the
progressive photobleaching of acceptor (figure 18B). This linear relationship was
preserved even at the highest levels of protein expression, suggesting that the dimer
does not proceed to higher order oligomerization. The SR membrane in the heart
contains abundant expression of SERCA. The junctional SR is estimated to contain more
than 50% SERCA and the longitudinal SR is estimated to contain as much as 90% SERCA
(Meissner 1975). Based on these estimates, we speculate that most of the SERCA in the
heart would be in a dimeric state.
It is interesting to note that the electrophoretic mobility of cross-linked SERCA
band 2 (230 kDa) is slightly greater than 2-fold that of the monomeric band 1 (99 kDa)
(figure 7B). Previous gel filtration experiments by Yamamoto et al. observed an apparent
78
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dimer fraction with electrophoretic mobility larger than 2-fold that of the monomer
(Yamamoto, Yantorno et al. 1984). This may indicate the presence of an accessory
protein in mediating homo-dimerization, although we did not identify any such protein.
We observed this phenomenon in both HEK cells (devoid of PLB) and rabbit LV
cardiomyocytes (containing abundant PLB), indicating that any such protein would have
to be present in both systems. Other work in our lab has shown that PLB is also captured
in our cross-linked species (data not published); although this alone does not account
for the 30 kDa shift.
Multiple types of experiments have indicated the presence of a SERCA homodimer in live cells. One problem that has eluded an answer thus far is the interface for
SERCA protomer interaction. Incubation of cells with various SERCA antibodies did not
produce alterations in dimer structure or affinity. However, the 6 custom antibodies
used all targeted the P-domain while the commercial antibody epitope was unknown.
This suggests the possibility that the P-domain is not the interface for dimerization;
however, this cannot be completely ruled out as antibody binding to SERCA in these
cells was not verified through immunohistochemistry. We also generated large
fragments of the SERCA peptide in an attempt to compete the SERCA homo-dimer FRET.
The short fragments localized to the cytoplasm, even when they contained parts of the
TM domain. We did not detect competition by these fragments, although a specific
short peptide may be capable of competing for the dimer interaction. If a precise
determination of the dimer interface is made, FRET competition by a short peptide
fragment could prove useful for verifying the interaction. This would be especially useful

80

to determine whether these peptides alter the functional effects that we observed in
this study.
Mass spectrometry could prove to be a useful tool for examining the site of
interaction. Cross-linking with BPM is irreversible, so extraction from the gel should
yield peptide fragment sizes that are altered. This technique may prove technically
challenging if multiple cross-links are present and include multiple accessory proteins.
We predict that another protein is present as the molecular weight of the cross-linked
SERCA is shifted by more than two-fold; however, mass spectrometry could prove useful
for identifying any such additional proteins. Our previous attempts to mutate four
different cysteines on SERCA were not successful in abrogating the cross-link formed by
BPM. It is possible that, while our data show a direct physical interaction between
SERCA protomers, the observed cross-link is due to reactivity of a cysteine on a partner
protein that forms a cross-link to a carbon on SERCA with the benzophenone group.
Thus mass spectrometry has great potential to identify any accessory proteins as well as
possibly identify the interface for SERCA dimerization.
While some studies have suggested that SERCA dimerization is a regulated
process, we did not see any evidence for this. Physical interaction between SERCA
protomers does not appear to be modulated, indicating a constitutively present homodimer. PLB was not required for homo-dimerization and SERCA conformational poise did
not alter binding affinity or homo-dimer structure. HAX-1 was previously shown to
regulate SERCA activity via PLB, however we did not detect a structural change in the
SERCA homo-oligomer. Although we did note that HAX-1 increases both SERCA and PLB
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expression, something that should be examined in more detail. Despite the large
structural change to SERCA that we detected with the addition of TG or calcium shown
here and previously (Hou, Hu et al. 2012, Pallikkuth, Blackwell et al. 2013), we did not
detect a change in the oligomeric state of SERCA, indicating that oligomerization is not
modulated be conformational poise. Inhibitors such as TG and melittin do not appear to
regulate SERCA function through interactions between SERCA protomers as others have
shown. It is interesting to note that the large structural changes to SERCA observed with
both calcium and TG did not alter oligomeric FRET, suggesting that the acceptor and
donor N-terminally labeled A-domains move in a coordinated fashion with binding of Ca
or TG.
In the present study we investigated the regulatory complex in detail using FRET
from SERCA to PLB. Steady state acceptor-sensitized FRET measurements of
fluorescently-labeled PLB and SERCA showed that FRET increased with protein
concentration, similar to previous measurements (Kelly, Hou et al. 2008, Hou and Robia
2010). Photobleaching revealed a linear relationship between the Cer-SERCA donor and
YFP-PLB acceptor, indicative of a single PLB in the regulatory complex. However these
data do not rule out the possibility of multiple Cer-SERCA donors in the complex.
Fluorescence lifetime measurements enabled us to resolve multiple FRET
subpopulations within a single cell. We observed that there are always donors that do
not participate in FRET, even at the highest protein concentrations where binding
interactions appear to approach saturation. One may consider several possible
interpretations of this result. There may simply be a fraction of SERCA that is
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inaccessible to PLB. We did not observe any mislocalization of SERCA fluorescence,
which was 100% colocalized with PLB, so any such sequestration of SERCA would have
to be in membrane microdomains that are below the resolution limit of fluorescence
microscopy. However, it seems implausible that the proportion of inaccessible SERCA
would decrease with increasing protein expression down to a minimum of almost
exactly 50% of total SERCA (figure 24D). A second alternative hypothesis is that only
SERCA molecules with the appropriate conformational poise can interact with PLB
(Chen, Stokes et al. 2003). Again, it seems surprising that this proportion of pumps in
the accessible state would titrate to 50%. Moreover, we have previously shown that
calcium only modestly alters the PLB-SERCA binding affinity (Bidwell, Blackwell et al.
2011), suggesting that PLB can bind to SERCA without regard to conformational poise.
Therefore, we interpret the present data as indicative of a model in which the SERCA
dimer interacts with PLB such that only one of the two donors in the complex may
perform FRET with the acceptor on PLB. Several structural schemes could satisfy this;
one simple arrangement is diagrammed in figure 27 where a dimer of SERCA protomers
interacts with a single PLB. The leftmost donor GFP, which is bound to the left/front
SERCA protomer (dotted outline), is >100 Å away from the mCherry (“R”), too far to
participate in FRET. The donor bound to the SERCA protomer on the right is 54 Å from
the mCherry, supporting robust FRET. Thus, no matter how much increasing protein
expression drives the equilibrium toward the bound complex, the population of donors
participating in FRET can never exceed 50% of the total. Thus, the maximal FRET
measured by steady-state methods (figure 20B)
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Figure 27. A model of the SERCA-SERCA-PLB regulatory complex in which the GFP on
one of the SERCA protomers (dotted outline) is too distant to participate in FRET with
PLB.
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(Kelly, Hou et al. 2008, Hou and Robia 2010) is half of that quantified from the short
lifetime component (τS) of a FRET donor fluorescence decay (figure 24C).
Previous estimates of the stoichiometry of the regulatory complex have
suggested that PLB binds to SERCA in a 1:1 relationship (Mueller, Karim et al. 2004).
However, studies have reported expression of SERCA and PLB to be anywhere from 1:5
to 4:1, indicating that PLB may not actually regulate SERCA in a 1:1 molar ratio in vivo
(Louis, Turnquist et al. 1987, Negash, Chen et al. 1996, Ceholski, Trieber et al. 2012). This
is supported by previous results using transgenic mice overexpressing PLB in the heart,
indicating that the native functional stoichiometry of the regulatory complex is less than
one PLB per SERCA (Kadambi, Ponniah et al. 1996). Furthermore, it has been noted that
a large quantity of PLB exists as the highly stable pentamer reserve pool, leaving less
monomers available for inhibition of the calcium ATPase. Our data may explain how full
inhibition of SERCA by PLB is observed even though estimates of PLB indicate that
expression might not be high enough for 1:1 binding.
While some studies have suggested that SERCA dimerization is a regulated by
PLB phosphorylation (Negash, Chen et al. 1996, Mahaney, Albers et al. 2005), we did not
observe a change in either the structure or the binding affinity of the homo-dimer in
response to PLB binding or PLB phosphorylation or Ca binding (figure 13). It is possible
that SERCA is always physically coupled, but PLB phosphorylation engages functional
coupling of the protomers. This hypothesis is compatible with reports that indicate that
phosphorylated PLB increases SERCA Vmax (Lu and Kirchberger 1994, Antipenko,
Spielman et al. 1997, Reddy, Cornea et al. 2003), (though other groups did not observe a
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Vmax change (Movsesian, Colyer et al. 1990, Morris, Cheng et al. 1991, Movsesian 1992,
Reddy, Jones et al. 1995, Odermatt, Kurzydlowski et al. 1996)). Importantly, PLBdependent functional coupling implies that phosphorylated PLB stays bound to SERCA
throughout the calcium transport cycle, a concept that is supported by many studies (Li,
Bigelow et al. 2004, Mueller, Karim et al. 2004, Bidwell, Blackwell et al. 2011) but not all
(Kimura, Kurzydlowski et al. 1997, Jones, Cornea et al. 2002). Our lab has previously
reported spectroscopic evidence for a particularly compact and ordered conformation
of SERCA when bound to phosphorylated PLB and calcium (Pallikkuth, Blackwell et al.
2013). This conformation may be the structural signature of functionally coupled SERCA
dimers.
Future experiments could take advantage of the other two labeled sites (509 and
C-term) to more accurately measure FRET, as this current study only examined the Nterm label in detail. These other sites may prove useful in triangulating the relative
positions of the Cer-SERCA N-term label relative to the YFP-labeled SERCA. Furthermore,
our model suggests that one SERCA in the homo-dimer is not capable of FRET with PLB
due to distance constraints. Fluorescence lifetime measurements from these other sites
may reveal two populations that are both capable of FRET with the YFP-PLB, thus giving
a better estimate of the position of the cytosolic domain of PLB relative to the SERCA
homo-dimer.
Previous studies suggested that SERCA homo-oligomerization is functionally
regulated by phosphorylated PLB. Several key functional studies suggested that SERCA
dimer activity is greater than the sum of its parts (Chamberlain, Berenski et al. 1983,
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Chen, Yao et al. 2009). However, detergent-solubilized SERCA1a, which is greater than
80% monomer, is still catalytically active (Vilsen and Andersen 1987), suggesting that
dimerization is not obligatory for function. However, our own cross-linking studies
showed that some dimers persist even under conditions of 1% DPC. Our data show two
important functional changes with PLB. First, the cooperativity of calcium-dependent
ATPase activity increases in cardiac microsomal preparations compared to skeletal
preparations, suggesting that this effect is modulated by interaction with PLB. Gorski et
al. also observed an increase in cooperativity with the addition of PLB, although they did
not attribute this increased cooperativity to functional coupling of SERCA protomers
(Gorski, Glaves et al. 2013). It is not yet clear whether this cooperativity is due to
physical association or activation of PLB. Second, we noted that phosphorylated PLB
alters Vmax, in agreement with a secondary role for regulation by phosphorylation (the
first being calcium sensitivity). Examination of detergent-solubilized SERCA suggests that
the composition of the lipid environment and the detergents used are crucial
determinants of SERCA activity (Vilsen and Andersen 1987, Gustavsson, Traaseth et al.
2011). This may help explain the inconsistency in past measurements of Vmax and
cooperativity in the literature. In fact, Gustavsson et al. showed that certain lipid
compositions had far more potent effects on both calcium sensitivity and V max than did
PLB (Gustavsson, Traaseth et al. 2011), indicating that the experimental conditions may
play a large role in the results obtained.
Further work in the field should examine the calcium ATPase activity to
determine how PLB increases cooperativity. SERCA calcium uptake in the absence of PLB
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has a Hill coefficient slightly less than 2 due to enhancement of the calcium binding
affinity at site II following calcium binding to site I. However, we detect increased
cooperativity in cardiac preparations that appears to be due to PLB. Further work should
examine how PLB modulates increased calcium sensitivity as this does not appear to be
dependent on phosphorylation, which is distinct from the Vmax alterations observed with
phosphorylation. Additional experiments should examine ATPase activity over the full
range of calcium to determine the effects of S16E on Vmax. Titration of PLB may provide
an interesting tool for determining the range of Vmax changes with phosphorylation.
Measurements should also be made to compare the present results with the Vmax
effects in microsomes expressing 100% wt SERCA or 100% D351A SERCA.
As mentioned in the introduction, multiple studies showed that phosphorylation
of PLB was unable to fully correct the decrease in SERCA activity observed in samples
obtained from HF. Our data may provide an explanation for decreased SERCA activity in
HF and the inability of phosphorylation of PLB to overcome reduced activity. Previous
studies have shown that SERCA activity is decreased more than expected for the change
in expression evidenced during HF (Schwinger, Bohm et al. 1995, Zarain-Herzberg, Afzal
et al. 1996) or in vivo (Chamberlain, Berenski et al. 1983). It is tempting to speculate that
decreases in SERCA activity observed during HF may be a result of functional coupling. If
a percentage of the SERCA protein becomes post-translationally modified such that it
cannot functionally couple with other SERCA protomers, then it would not be able to
achieve a similar rate of calcium transport. Combined with reduced levels of PLB
phosphorylation observed in HF, SERCA activity would be reduced even further as
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evidenced in figure 26D. This may also explain why a recent clinical trial to overexpress
SERCA was not successful, as the endogenous SERCA in HF acts in a dominant negative
fashion to prevent exogenously-expressed SERCA from reaching full rates of calcium
transport. In fact, in vivo studies have shown that certain post-translational
modifications reduce SERCA activity (Lancel, Qin et al. 2010). I hypothesize that these
pumps may act in a dominant negative fashion; that is, they physically couple with other
SERCA protomers but do not contribute enzymatically.
Conclusion
The functional implication of a single PLB regulating a pair of SERCA is unclear,
however one may speculate that this stoichiometry would make PLB relatively more
potent in modulating transport activity. In particular, estimates of the in vivo expression
ratio of PLB to SERCA range from 1:5 to 4:1, and a substantial portion (~80%) of the PLB
is pentameric and therefore inaccessible to SERCA (Cornea, Jones et al. 1997).
Regulation of two SERCA pumps by a single PLB would explain this apparent regulatory
protein expression mismatch. The stoichiometry may also account for the greater
cooperativity of Ca-ATPase activity in cardiac muscle compared to skeletal muscle
lacking PLB. If PLB engages functional coupling of the two SERCA molecules, the number
of Ca-binding sites per transport unit is effectively increased. Indeed, some
superinhibitory PLB mutants can deliver Hill coefficients that exceed 2 (Trieber, Afara et
al. 2009). Finally, the present results have implications for human disease, particularly
heart failure, in which SERCA activity is decreased as a result of changes in SERCA:PLB
ratios, SERCA expression levels (Hasenfuss, Reinecke et al. 1994) or changes in SERCA
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specific activity (Schwinger, Bohm et al. 1995, Schmidt, Hajjar et al. 1999). The present
results suggest that deviation from optimal protein expression level or damage to a
fraction of the SERCA population may yield a larger than expected functional deficit as a
consequence of altered conformational coupling.
Our data support a quaternary regulatory complex containing a single PLB bound
to a pair of SERCA protomers. We observe SERCA2a dimers in the absence/presence of
PLB and the dimers do not require PLB phosphorylation in order to assemble. Moreover,
cross-linking experiments suggest that SERCA2a readily forms dimers in the native
environment of the sarcoplasmic reticulum membrane of the cardiac muscle cell. SERCA
dimers are functionally coupled by PLB, which increases cooperativity of calcium binding
and alters Vmax.
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